data_5kkm_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 5kkm _Structure_validation_residue.Date_analyzed 2017-05-26 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.689 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 35.0 m-85 -118.68 141.27 48.77 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.777 0.322 . . . . 0.0 110.549 179.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.81 133.02 55.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.215 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 91.5 t80 -63.83 131.23 47.14 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.072 -179.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -111.71 112.87 53.36 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.972 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -73.25 -32.08 8.68 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 C-N-CA 121.269 1.313 . . . . 0.0 111.465 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 63.6 t -64.65 -45.62 94.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.47 179.096 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 83.3 mt -82.85 -27.19 30.97 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.392 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.68 3.33 90.55 Favored Glycine 0 CA--C 1.528 0.88 0 N-CA-C 111.367 -0.693 . . . . 0.0 111.367 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.419 ' C ' ' CD1' ' A' ' 15' ' ' ILE . 2.4 pp -133.18 172.73 15.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 120.812 0.339 . . . . 0.0 110.805 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 83.8 m -87.71 137.92 31.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.203 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.0 p -127.6 153.62 46.2 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.922 0.391 . . . . 0.0 110.504 179.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.5 tt . . . . . 0 C--N 1.328 -0.364 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.559 -179.069 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.819 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.5 m-85 -112.64 143.84 43.15 Favored 'General case' 0 C--N 1.333 -0.119 0 N-CA-C 110.217 -0.29 . . . . 0.0 110.217 179.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.3 133.92 54.87 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.607 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 91.7 t80 -64.22 131.72 48.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.854 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -112.37 113.4 51.22 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.073 178.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -73.39 -32.46 8.03 Favored 'Trans proline' 0 N--CA 1.487 1.144 0 C-N-CA 121.294 1.33 . . . . 0.0 111.628 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.0 t -64.57 -45.86 94.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.422 179.305 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 85.3 mt -81.19 -26.61 35.83 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.352 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.58 3.07 90.67 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 111.289 -0.724 . . . . 0.0 111.289 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.42 ' C ' ' CD1' ' A' ' 15' ' ' ILE . 2.4 pp -134.15 173.18 15.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 120.913 0.387 . . . . 0.0 110.771 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 58.2 m -87.93 136.73 32.83 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.132 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.0 p -127.58 154.85 44.71 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-O 120.978 0.418 . . . . 0.0 110.713 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.4 tt . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.541 -179.355 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.841 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.5 m-85 -112.27 141.72 45.64 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 120.701 0.286 . . . . 0.0 110.377 179.62 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -110.82 133.27 53.5 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.447 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 91.9 t80 -63.83 131.42 47.72 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.862 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -112.87 113.11 50.06 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.048 179.01 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -73.43 -32.06 8.39 Favored 'Trans proline' 0 C--N 1.316 -1.161 0 C-N-CA 121.302 1.334 . . . . 0.0 111.607 -179.739 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.7 t -64.41 -45.89 94.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.412 179.117 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 85.0 mt -81.84 -26.54 34.2 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.262 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.66 3.29 90.57 Favored Glycine 0 CA--C 1.527 0.802 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.418 ' C ' ' CD1' ' A' ' 15' ' ' ILE . 2.4 pp -134.2 172.98 15.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 120.857 0.361 . . . . 0.0 110.786 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.8 m -88.49 137.68 32.11 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.265 -0.425 . . . . 0.0 109.862 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.3 p -127.65 155.28 44.16 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.978 0.418 . . . . 0.0 110.777 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.8 tt . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.354 -179.371 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.801 0 N-CA-C 110.066 -1.214 . . . . 0.0 110.066 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.2 m-85 -108.47 145.77 34.17 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 179.308 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -123.26 134.83 54.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.1 -179.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -60.43 131.13 49.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.068 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.64 114.04 47.46 Favored Pre-proline 0 CA--C 1.533 0.299 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.739 179.052 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -72.22 -30.37 13.16 Favored 'Trans proline' 0 C--N 1.315 -1.192 0 C-N-CA 121.363 1.376 . . . . 0.0 111.49 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.5 t -64.04 -45.56 96.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.094 178.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 85.4 mt -84.83 -24.48 28.61 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.293 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.43 0.67 90.08 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.414 ' C ' ' CD1' ' A' ' 15' ' ' ILE . 2.5 pp -136.23 170.87 17.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.699 0.285 . . . . 0.0 110.618 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 93.9 m -87.57 141.2 28.79 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.908 0.385 . . . . 0.0 110.92 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.9 p -129.06 156.97 43.0 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.111 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.4 tt . . . . . 0 C--N 1.327 -0.388 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.254 -179.742 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.716 0 N-CA-C 110.057 -1.217 . . . . 0.0 110.057 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 27.4 m-85 -108.99 146.75 33.36 Favored 'General case' 0 C--N 1.332 -0.164 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -125.01 135.61 52.93 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.031 0.443 . . . . 0.0 111.076 -179.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -60.47 131.57 51.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.123 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.86 114.31 46.75 Favored Pre-proline 0 CA--C 1.534 0.36 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.725 179.032 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -71.92 -30.45 13.92 Favored 'Trans proline' 0 C--N 1.315 -1.203 0 C-N-CA 121.329 1.353 . . . . 0.0 111.594 -179.455 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.9 t -64.13 -45.45 96.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.085 178.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.6 mt -85.3 -24.65 27.61 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.389 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.32 0.9 90.23 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.416 ' C ' ' CD1' ' A' ' 15' ' ' ILE . 2.5 pp -135.82 171.1 17.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.682 0.277 . . . . 0.0 110.464 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 99.1 m -87.94 140.97 28.96 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.875 0.369 . . . . 0.0 110.954 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.2 p -128.89 156.96 42.86 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.932 179.645 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt . . . . . 0 C--N 1.328 -0.358 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.382 -179.548 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.768 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 26.4 m-85 -108.42 146.12 33.57 Favored 'General case' 0 C--N 1.332 -0.154 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 179.215 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -123.89 135.43 53.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.953 0.406 . . . . 0.0 111.144 -179.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.8 t80 -60.45 131.61 51.29 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.041 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -114.03 114.21 46.33 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.769 179.017 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -71.93 -30.5 13.84 Favored 'Trans proline' 0 C--N 1.316 -1.136 0 C-N-CA 121.388 1.392 . . . . 0.0 111.552 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.2 t -64.16 -45.62 95.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.208 179.019 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.7 mt -84.86 -24.41 28.58 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.423 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.31 0.86 90.19 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.42 ' C ' ' CD1' ' A' ' 15' ' ' ILE . 2.5 pp -135.91 171.34 17.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 120.668 0.27 . . . . 0.0 110.557 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 99.1 m -87.98 141.21 28.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.946 0.403 . . . . 0.0 110.792 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.9 p -129.01 157.09 42.67 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.074 179.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.2 tt . . . . . 0 C--N 1.327 -0.371 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.311 -179.632 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.777 0 N-CA-C 110.154 -1.178 . . . . 0.0 110.154 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.6 m-85 -109.51 147.51 32.8 Favored 'General case' 0 C--N 1.333 -0.12 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.266 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -126.17 136.1 52.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.941 0.4 . . . . 0.0 111.126 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 92.8 t80 -60.05 131.34 50.54 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.997 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -115.59 114.17 42.46 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.884 179.088 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -72.26 -30.76 12.6 Favored 'Trans proline' 0 C--N 1.315 -1.189 0 C-N-CA 121.217 1.278 . . . . 0.0 111.452 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.13 -45.22 97.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.361 178.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 82.4 mt -85.36 -22.08 28.6 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.442 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.64 -0.5 89.55 Favored Glycine 0 CA--C 1.53 0.999 0 CA-C-N 116.131 -0.486 . . . . 0.0 112.16 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -141.05 176.56 4.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.734 179.703 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 93.0 m -88.05 139.89 30.05 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.02 0.438 . . . . 0.0 111.149 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.5 p -129.15 156.7 43.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.962 179.605 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt . . . . . 0 C--N 1.327 -0.411 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.246 -179.658 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.825 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 26.2 m-85 -112.73 144.24 42.59 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 179.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.92 133.76 55.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.35 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.0 t80 -63.82 130.67 45.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.938 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.04 112.09 50.23 Favored Pre-proline 0 CA--C 1.532 0.273 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.449 179.306 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -74.05 -32.19 7.2 Favored 'Trans proline' 0 C--N 1.317 -1.1 0 C-N-CA 121.397 1.398 . . . . 0.0 111.367 -179.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.8 -44.89 96.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.547 179.296 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 76.8 mt -83.38 -22.51 32.74 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.197 -179.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.18 2.3 90.47 Favored Glycine 0 CA--C 1.53 0.975 0 CA-C-N 116.151 -0.477 . . . . 0.0 112.617 179.003 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.2 179.72 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-N 117.308 0.554 . . . . 0.0 111.073 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 59.7 m -88.33 137.13 32.6 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.813 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.6 p -128.18 156.75 42.42 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-O 121.038 0.447 . . . . 0.0 110.826 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.0 tt . . . . . 0 C--N 1.33 -0.241 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.553 -179.109 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.814 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 21.3 m-85 -112.04 142.68 44.17 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 179.565 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.41 133.94 54.22 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.558 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.52 130.79 45.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.913 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -114.14 112.99 46.62 Favored Pre-proline 0 CA--C 1.533 0.289 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.272 179.099 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -73.78 -32.79 7.05 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 C-N-CA 121.301 1.334 . . . . 0.0 111.454 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 63.6 t -64.27 -45.66 95.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.497 179.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.1 mt -81.38 -24.66 36.86 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.395 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.01 1.53 88.72 Favored Glycine 0 CA--C 1.532 1.151 0 CA-C-N 116.189 -0.46 . . . . 0.0 112.595 179.139 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -139.1 179.31 3.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 117.47 0.635 . . . . 0.0 111.043 179.614 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 37.4 m -88.97 135.58 33.47 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 109.878 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.7 p -127.65 154.59 45.09 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-O 121.005 0.431 . . . . 0.0 110.805 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.3 tt . . . . . 0 C--N 1.33 -0.239 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.459 -179.35 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.711 0 N-CA-C 110.154 -1.179 . . . . 0.0 110.154 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 26.1 m-85 -112.37 143.93 42.66 Favored 'General case' 0 N--CA 1.462 0.157 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.2 134.22 54.68 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.551 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 86.9 t80 -63.4 130.97 46.7 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.891 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -114.56 112.07 46.01 Favored Pre-proline 0 CA--C 1.534 0.344 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.337 179.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -73.88 -32.32 7.36 Favored 'Trans proline' 0 C--N 1.316 -1.134 0 C-N-CA 121.338 1.359 . . . . 0.0 111.413 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.5 t -64.71 -45.07 96.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.684 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 76.8 mt -83.06 -22.65 33.44 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.117 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.25 2.66 90.37 Favored Glycine 0 CA--C 1.53 0.974 0 CA-C-N 116.168 -0.469 . . . . 0.0 112.51 179.013 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.68 179.54 3.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 117.209 0.505 . . . . 0.0 111.07 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 38.3 m -88.78 134.94 33.77 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.2 p -126.55 154.46 43.83 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 121.012 0.434 . . . . 0.0 110.73 -179.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.2 tt . . . . . 0 C--N 1.328 -0.363 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.791 -179.158 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.018 0 N-CA-C 111.783 -0.527 . . . . 0.0 111.783 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -120.29 143.61 48.25 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.743 0.306 . . . . 0.0 110.559 179.603 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -111.42 130.1 55.81 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.922 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -63.87 130.96 46.25 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.865 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -112.24 112.99 51.83 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.108 179.214 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -73.35 -31.81 8.79 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.266 1.31 . . . . 0.0 111.487 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.3 t -64.59 -45.89 94.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.363 179.13 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.0 mt -82.25 -27.14 32.63 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.365 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.67 3.69 90.4 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.415 -0.674 . . . . 0.0 111.415 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.416 ' C ' ' CD1' ' A' ' 15' ' ' ILE . 2.4 pp -133.46 173.03 15.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-O 120.878 0.37 . . . . 0.0 110.923 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 69.0 m -88.33 136.38 33.01 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.065 -179.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.2 p -126.39 151.26 47.89 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-O 120.958 0.408 . . . . 0.0 110.628 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.3 tt . . . . . 0 C--N 1.327 -0.388 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.563 -179.078 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.93 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -113.28 143.6 44.14 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 179.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.25 133.89 54.86 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.423 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 89.2 t80 -63.48 131.03 46.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.045 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -113.98 112.12 47.59 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.404 179.288 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -73.99 -32.13 7.36 Favored 'Trans proline' 0 C--N 1.316 -1.147 0 C-N-CA 121.349 1.366 . . . . 0.0 111.458 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.68 -45.13 96.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.573 179.215 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 77.7 mt -82.63 -22.77 34.6 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.254 -179.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.35 2.37 90.28 Favored Glycine 0 CA--C 1.529 0.955 0 CA-C-N 116.086 -0.506 . . . . 0.0 112.574 179.195 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.98 179.43 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.172 0 CA-C-N 117.209 0.504 . . . . 0.0 111.027 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.4 m -88.81 136.3 33.07 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.774 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.9 p -127.66 156.22 42.68 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-O 120.98 0.419 . . . . 0.0 110.816 -179.783 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.8 tt . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.495 -179.258 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.911 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 29.9 m-85 -114.79 144.35 43.64 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.666 0.269 . . . . 0.0 110.406 179.754 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.59 133.3 54.7 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.243 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.28 131.16 47.44 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.857 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.89 112.22 47.79 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.504 179.345 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -74.38 -31.74 7.05 Favored 'Trans proline' 0 C--N 1.317 -1.112 0 C-N-CA 121.374 1.383 . . . . 0.0 111.271 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.1 t -64.67 -44.94 96.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.47 179.198 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 76.9 mt -83.8 -22.51 31.78 Favored 'General case' 0 CA--C 1.529 0.154 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.262 -179.572 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.44 2.14 90.19 Favored Glycine 0 CA--C 1.531 1.042 0 CA-C-N 116.199 -0.455 . . . . 0.0 112.573 179.125 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.07 -179.11 2.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 117.214 0.507 . . . . 0.0 111.018 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.7 m -90.8 134.96 34.04 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.177 -0.465 . . . . 0.0 109.84 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 78.5 p -127.1 153.28 46.2 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-O 120.95 0.405 . . . . 0.0 110.877 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.3 tt . . . . . 0 C--N 1.328 -0.351 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.652 -179.16 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.798 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -112.12 143.05 43.8 Favored 'General case' 0 C--N 1.332 -0.162 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.63 133.86 54.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.629 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 84.3 t80 -63.2 130.48 44.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.808 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.18 112.22 49.77 Favored Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.347 179.203 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -73.84 -32.11 7.63 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.282 1.322 . . . . 0.0 111.369 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 63.7 t -64.4 -45.07 96.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.505 179.136 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 78.4 mt -83.6 -23.53 31.86 Favored 'General case' 0 CA--C 1.529 0.161 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.294 -179.561 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.09 1.63 89.59 Favored Glycine 0 CA--C 1.53 0.995 0 CA-C-N 116.35 -0.386 . . . . 0.0 112.569 178.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.15 177.41 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 117.347 0.574 . . . . 0.0 110.975 179.727 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.3 m -87.76 135.27 33.45 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.5 p -127.51 154.47 45.1 Favored 'General case' 0 N--CA 1.462 0.146 0 CA-C-O 120.926 0.393 . . . . 0.0 110.853 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.6 tt . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.457 -179.397 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.724 0 N-CA-C 110.737 -0.945 . . . . 0.0 110.737 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 33.1 m-85 -117.16 140.35 49.63 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 110.273 -0.269 . . . . 0.0 110.273 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.99 133.76 54.8 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.349 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 88.2 t80 -62.44 131.47 49.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.921 -179.768 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -114.07 112.26 47.26 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.393 179.028 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -73.61 -31.79 8.36 Favored 'Trans proline' 0 N--CA 1.487 1.103 0 C-N-CA 121.373 1.382 . . . . 0.0 111.404 -179.682 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.0 t -64.93 -44.85 96.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.412 179.333 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 77.0 mt -83.85 -23.64 31.25 Favored 'General case' 0 CA--C 1.53 0.189 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.27 -179.602 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.84 1.62 89.84 Favored Glycine 0 CA--C 1.531 1.077 0 CA-C-N 116.073 -0.512 . . . . 0.0 112.53 179.027 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.16 177.85 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 117.349 0.575 . . . . 0.0 111.056 179.807 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 63.1 m -86.29 137.26 32.74 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.13 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.6 p -128.15 154.37 45.85 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-O 120.797 0.332 . . . . 0.0 110.746 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.5 tt . . . . . 0 C--N 1.327 -0.384 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.585 -179.202 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.788 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 28.6 m-85 -109.89 146.58 34.9 Favored 'General case' 0 C--O 1.233 0.189 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 179.181 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -124.92 135.39 52.8 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.936 0.398 . . . . 0.0 111.151 -179.469 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -60.29 131.19 50.02 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.113 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.4 114.17 48.02 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.696 178.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -71.82 -30.34 14.36 Favored 'Trans proline' 0 C--N 1.316 -1.164 0 C-N-CA 121.304 1.336 . . . . 0.0 111.525 -179.539 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.3 t -64.2 -45.42 96.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.141 178.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.0 mt -85.43 -24.43 27.47 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.436 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.21 0.89 90.16 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 -179.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.414 ' C ' ' CD1' ' A' ' 15' ' ' ILE . 2.5 pp -135.66 171.16 17.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 120.661 0.267 . . . . 0.0 110.557 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 96.7 m -88.06 141.23 28.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.975 0.417 . . . . 0.0 111.015 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.8 p -128.99 157.05 42.77 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.116 179.465 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt . . . . . 0 C--N 1.326 -0.432 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.446 -179.545 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.836 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.0 m-85 -112.57 143.35 43.89 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 179.506 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -114.12 133.9 55.25 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.598 -179.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 85.6 t80 -62.94 131.02 47.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.917 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -113.96 112.77 47.26 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.262 179.222 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -73.39 -32.52 7.98 Favored 'Trans proline' 0 C--N 1.316 -1.182 0 C-N-CA 121.34 1.36 . . . . 0.0 111.436 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 64.7 t -64.86 -45.29 95.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.653 179.274 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 81.5 mt -81.91 -24.34 35.7 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.363 -179.67 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.21 1.51 89.51 Favored Glycine 0 CA--C 1.531 1.051 0 CA-C-N 116.214 -0.448 . . . . 0.0 112.639 179.122 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.401 HG22 HD12 ' A' ' 15' ' ' ILE . 0.0 OUTLIER -139.06 176.9 5.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 117.366 0.583 . . . . 0.0 111.032 179.67 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 38.8 m -85.78 135.25 33.81 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.6 p -127.95 155.26 44.52 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-O 120.978 0.418 . . . . 0.0 110.845 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.3 tt . . . . . 0 C--N 1.331 -0.226 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.582 -179.348 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.825 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.9 m-85 -112.97 144.72 42.06 Favored 'General case' 0 N--CA 1.462 0.138 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 179.678 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.93 133.89 55.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.548 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -63.66 130.92 46.27 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.82 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.28 112.27 49.46 Favored Pre-proline 0 CA--C 1.533 0.301 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.403 179.349 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -74.21 -31.99 7.12 Favored 'Trans proline' 0 C--N 1.317 -1.108 0 C-N-CA 121.399 1.399 . . . . 0.0 111.337 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.9 t -64.5 -45.01 96.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.513 179.216 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 74.9 mt -83.66 -22.75 32.05 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.325 -179.351 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.39 2.47 90.22 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-N 116.245 -0.434 . . . . 0.0 112.456 179.115 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.23 -179.87 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-N 117.23 0.515 . . . . 0.0 111.07 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 59.1 m -90.3 135.56 33.6 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.953 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.5 p -127.89 154.46 45.48 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 120.98 0.419 . . . . 0.0 110.792 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.7 tt . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.568 -179.342 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.735 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 32.6 m-85 -112.04 145.98 38.72 Favored 'General case' 0 C--N 1.333 -0.116 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 179.265 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -124.13 135.86 53.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.083 0.468 . . . . 0.0 111.137 -179.257 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 89.8 t80 -60.34 131.51 51.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.196 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.99 114.43 46.34 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.61 178.829 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -71.93 -30.76 13.49 Favored 'Trans proline' 0 C--N 1.315 -1.188 0 C-N-CA 121.255 1.303 . . . . 0.0 111.708 -179.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.2 t -64.26 -45.45 96.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.264 178.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.7 mt -84.54 -24.76 29.16 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.409 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.34 0.74 90.09 Favored Glycine 0 CA--C 1.527 0.831 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.42 ' C ' ' CD1' ' A' ' 15' ' ' ILE . 2.5 pp -135.26 171.68 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.597 0.237 . . . . 0.0 110.463 179.806 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 92.4 m -88.79 140.94 28.93 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.073 0.464 . . . . 0.0 110.976 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.8 p -128.41 155.92 43.98 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.838 179.506 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.4 tt . . . . . 0 C--N 1.327 -0.395 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.139 -179.421 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.79 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 46.9 m-85 -113.94 142.07 46.6 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 120.648 0.261 . . . . 0.0 110.426 179.576 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -110.24 132.49 54.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.082 179.474 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -64.03 131.64 48.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.012 -179.637 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -112.73 113.63 50.09 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.122 178.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -73.3 -32.71 7.93 Favored 'Trans proline' 0 C--N 1.316 -1.144 0 C-N-CA 121.257 1.305 . . . . 0.0 111.598 -179.646 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.3 t -64.38 -46.03 94.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.529 179.262 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.6 mt -81.54 -27.07 34.55 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.303 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.73 2.99 90.69 Favored Glycine 0 CA--C 1.528 0.845 0 N-CA-C 111.342 -0.703 . . . . 0.0 111.342 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ILE . . . . . 0.422 ' C ' ' CD1' ' A' ' 15' ' ' ILE . 2.4 pp -133.03 173.44 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.173 0 CA-C-O 120.865 0.364 . . . . 0.0 110.689 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 48.3 m -87.8 136.89 32.76 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.039 -179.578 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.3 p -128.55 154.23 46.38 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 121.372 0.606 . . . . 0.0 111.287 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.412 HG23 HD12 ' A' ' 18' ' ' ILE . 0.4 OUTLIER . . . . . 0 C--N 1.325 -0.459 0 CA-C-N 115.223 -0.898 . . . . 0.0 110.462 -179.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 18.1 mt-30 . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.82 0.343 . . . . 0.0 110.494 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.7 t90 -135.17 129.15 33.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.366 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 64.7 m -111.26 133.75 53.36 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.545 -179.739 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.583 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 6.5 pm0 -71.64 159.0 86.76 Favored Pre-proline 0 CA--C 1.536 0.441 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.34 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_exo -52.28 140.12 52.82 Favored 'Trans proline' 0 N--CA 1.498 1.751 0 C-N-CA 121.263 1.309 . . . . 0.0 111.833 179.739 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 91.75 -7.87 78.99 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -179.569 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.507 ' CG ' ' NE2' ' A' ' 4' ' ' GLN . 35.0 m-85 -118.68 141.27 48.77 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.777 0.322 . . . . 0.0 110.549 179.715 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.81 133.02 55.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.215 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 91.5 t80 -63.83 131.23 47.14 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.072 -179.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -111.71 112.87 53.36 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.972 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -73.25 -32.08 8.68 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 C-N-CA 121.269 1.313 . . . . 0.0 111.465 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 63.6 t -64.65 -45.62 94.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.47 179.096 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 83.3 mt -82.85 -27.19 30.97 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.392 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.68 3.33 90.55 Favored Glycine 0 CA--C 1.528 0.88 0 N-CA-C 111.367 -0.693 . . . . 0.0 111.367 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.419 ' C ' ' CD1' ' A' ' 15' ' ' ILE . 2.4 pp -133.18 172.73 15.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 120.812 0.339 . . . . 0.0 110.805 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 83.8 m -87.71 137.92 31.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.203 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.0 p -127.6 153.62 46.2 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.922 0.391 . . . . 0.0 110.504 179.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.5 tt -72.72 149.91 8.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.559 -179.069 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.6 t -149.63 148.56 29.46 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.129 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -120.29 -13.44 8.89 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.411 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 51.0 m 53.59 39.96 30.79 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.811 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 61.2 ttp180 . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.125 -0.94 . . . . 0.0 110.511 179.874 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . 0.464 ' N ' ' OE1' ' A' ' 1' ' ' GLN . 13.1 pm0 . . . . . 0 N--CA 1.457 -0.108 0 CA-C-O 120.817 0.341 . . . . 0.0 110.703 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.5 t90 -138.62 132.9 31.7 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.533 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 74.2 m -118.85 150.37 39.96 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.563 179.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.657 ' H ' ' NE2' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -72.97 162.34 75.01 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.712 179.23 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -65.14 138.9 58.38 Favored 'Trans proline' 0 C--N 1.302 -1.916 0 C-N-CA 121.698 1.599 . . . . 0.0 110.765 179.333 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.43 -7.81 81.18 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 -178.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.5 m-85 -112.64 143.84 43.15 Favored 'General case' 0 C--N 1.333 -0.119 0 N-CA-C 110.217 -0.29 . . . . 0.0 110.217 179.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.3 133.92 54.87 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.607 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 91.7 t80 -64.22 131.72 48.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.854 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -112.37 113.4 51.22 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.073 178.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -73.39 -32.46 8.03 Favored 'Trans proline' 0 N--CA 1.487 1.144 0 C-N-CA 121.294 1.33 . . . . 0.0 111.628 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.0 t -64.57 -45.86 94.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.422 179.305 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 85.3 mt -81.19 -26.61 35.83 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.352 -179.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.58 3.07 90.67 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 111.289 -0.724 . . . . 0.0 111.289 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.42 ' C ' ' CD1' ' A' ' 15' ' ' ILE . 2.4 pp -134.15 173.18 15.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 120.913 0.387 . . . . 0.0 110.771 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 58.2 m -87.93 136.73 32.83 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.132 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.0 p -127.58 154.85 44.71 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-O 120.978 0.418 . . . . 0.0 110.713 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.4 tt -72.98 149.08 8.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.541 -179.355 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 10.3 t -151.13 143.76 24.36 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.0 mt -129.95 144.23 51.22 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.642 -179.702 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.0 t -61.1 -44.33 97.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.955 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.608 -179.786 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . 0.449 ' N ' ' CE1' ' A' ' 9' ' ' TYR . 22.9 mm100 . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.87 0.367 . . . . 0.0 110.613 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.6 t90 -66.03 132.94 49.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.793 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.6 m -118.58 150.41 39.72 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.435 179.739 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.668 ' H ' ' NE2' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -72.87 162.15 75.84 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.702 179.334 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -64.57 138.28 58.63 Favored 'Trans proline' 0 C--N 1.302 -1.917 0 C-N-CA 121.609 1.539 . . . . 0.0 110.898 179.494 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.82 -7.77 81.11 Favored Glycine 0 CA--C 1.527 0.841 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -178.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.5 m-85 -112.27 141.72 45.64 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 120.701 0.286 . . . . 0.0 110.377 179.62 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -110.82 133.27 53.5 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.447 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.449 ' CE1' ' N ' ' A' ' 1' ' ' GLN . 91.9 t80 -63.83 131.42 47.72 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.862 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -112.87 113.11 50.06 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.048 179.01 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -73.43 -32.06 8.39 Favored 'Trans proline' 0 C--N 1.316 -1.161 0 C-N-CA 121.302 1.334 . . . . 0.0 111.607 -179.739 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.7 t -64.41 -45.89 94.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.412 179.117 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 85.0 mt -81.84 -26.54 34.2 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.262 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.66 3.29 90.57 Favored Glycine 0 CA--C 1.527 0.802 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.418 ' C ' ' CD1' ' A' ' 15' ' ' ILE . 2.4 pp -134.2 172.98 15.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 120.857 0.361 . . . . 0.0 110.786 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.8 m -88.49 137.68 32.11 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.265 -0.425 . . . . 0.0 109.862 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.3 p -127.65 155.28 44.16 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.978 0.418 . . . . 0.0 110.777 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.8 tt -76.5 144.57 11.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.354 -179.371 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' THR . . . . . 0.418 ' OG1' ' O ' ' A' ' 22' ' ' ARG . 9.1 t -146.27 145.0 30.22 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.674 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -140.69 -71.33 0.37 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.455 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 96.3 p -65.42 -23.05 66.85 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.819 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.418 ' O ' ' OG1' ' A' ' 19' ' ' THR . 80.1 ttt180 . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 118.1 -0.952 . . . . 0.0 110.429 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 19.8 mt-30 . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.799 0.333 . . . . 0.0 110.54 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.0 t90 -66.94 128.69 37.29 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.526 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.7 m -121.03 127.07 51.38 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.46 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.595 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.8 OUTLIER -52.3 154.51 4.19 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.567 -179.619 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo -64.49 146.3 89.14 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 121.634 1.556 . . . . 0.0 110.983 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 92.21 -8.26 77.72 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.066 -1.214 . . . . 0.0 110.066 -178.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.2 m-85 -108.47 145.77 34.17 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 179.308 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -123.26 134.83 54.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.1 -179.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -60.43 131.13 49.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.068 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.64 114.04 47.46 Favored Pre-proline 0 CA--C 1.533 0.299 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.739 179.052 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -72.22 -30.37 13.16 Favored 'Trans proline' 0 C--N 1.315 -1.192 0 C-N-CA 121.363 1.376 . . . . 0.0 111.49 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.5 t -64.04 -45.56 96.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.094 178.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 85.4 mt -84.83 -24.48 28.61 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.293 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.43 0.67 90.08 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.414 ' C ' ' CD1' ' A' ' 15' ' ' ILE . 2.5 pp -136.23 170.87 17.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.699 0.285 . . . . 0.0 110.618 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 93.9 m -87.57 141.2 28.79 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.908 0.385 . . . . 0.0 110.92 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.9 p -129.06 156.97 43.0 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.111 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.4 tt -71.16 152.5 8.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.254 -179.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 81.5 p -125.11 152.02 44.93 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.292 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.469 ' O ' ' CB ' ' A' ' 21' ' ' SER . 0.3 OUTLIER -136.71 -29.83 0.92 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.552 -179.857 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.469 ' CB ' ' O ' ' A' ' 20' ' ' LEU . 1.7 p 79.16 158.36 0.17 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.456 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 9.3 ptm85 . . . . . 0 C--O 1.219 -0.536 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.536 -179.811 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 28.1 mm100 . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.662 0.268 . . . . 0.0 110.532 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.8 t90 -110.79 123.05 49.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.56 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 76.6 m -117.02 126.48 52.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.421 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.587 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.9 OUTLIER -51.2 154.33 2.87 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.471 -179.536 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -64.57 146.57 89.35 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 121.599 1.532 . . . . 0.0 110.944 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 92.17 -8.21 77.84 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.057 -1.217 . . . . 0.0 110.057 -178.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 27.4 m-85 -108.99 146.75 33.36 Favored 'General case' 0 C--N 1.332 -0.164 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.296 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -125.01 135.61 52.93 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.031 0.443 . . . . 0.0 111.076 -179.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -60.47 131.57 51.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.123 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.86 114.31 46.75 Favored Pre-proline 0 CA--C 1.534 0.36 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.725 179.032 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -71.92 -30.45 13.92 Favored 'Trans proline' 0 C--N 1.315 -1.203 0 C-N-CA 121.329 1.353 . . . . 0.0 111.594 -179.455 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.9 t -64.13 -45.45 96.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.085 178.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.6 mt -85.3 -24.65 27.61 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.389 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.32 0.9 90.23 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.416 ' C ' ' CD1' ' A' ' 15' ' ' ILE . 2.5 pp -135.82 171.1 17.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.682 0.277 . . . . 0.0 110.464 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 99.1 m -87.94 140.97 28.96 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.875 0.369 . . . . 0.0 110.954 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.2 p -128.89 156.96 42.86 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.932 179.645 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt -68.36 149.93 11.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.382 -179.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 80.5 p -129.82 155.17 46.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.09 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 61.8 tp -118.52 123.99 46.46 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.142 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.4 ' O ' ' O ' ' A' ' 22' ' ' ARG . 51.4 m 54.87 39.62 31.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.383 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.4 ' O ' ' O ' ' A' ' 21' ' ' SER . 43.8 ttm180 . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 118.037 -0.983 . . . . 0.0 110.541 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 96.9 mm-40 . . . . . 0 C--O 1.23 0.048 0 CA-C-O 120.721 0.296 . . . . 0.0 110.421 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.8 t90 -118.15 122.83 44.04 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.508 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 74.4 m -117.2 125.87 51.87 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.469 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.599 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.8 OUTLIER -50.2 154.52 2.01 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.467 -179.505 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -64.8 146.29 87.98 Favored 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 121.566 1.511 . . . . 0.0 111.018 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 92.06 -8.16 78.09 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 -178.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 26.4 m-85 -108.42 146.12 33.57 Favored 'General case' 0 C--N 1.332 -0.154 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 179.215 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -123.89 135.43 53.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.953 0.406 . . . . 0.0 111.144 -179.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.8 t80 -60.45 131.61 51.29 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.041 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -114.03 114.21 46.33 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.769 179.017 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -71.93 -30.5 13.84 Favored 'Trans proline' 0 C--N 1.316 -1.136 0 C-N-CA 121.388 1.392 . . . . 0.0 111.552 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.2 t -64.16 -45.62 95.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.208 179.019 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.7 mt -84.86 -24.41 28.58 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.423 179.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.31 0.86 90.19 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.42 ' C ' ' CD1' ' A' ' 15' ' ' ILE . 2.5 pp -135.91 171.34 17.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 120.668 0.27 . . . . 0.0 110.557 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 99.1 m -87.98 141.21 28.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.946 0.403 . . . . 0.0 110.792 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.9 p -129.01 157.09 42.67 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.074 179.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.2 tt -69.36 151.65 9.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.311 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 80.5 p -128.26 154.73 45.57 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.154 179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 61.6 tp -122.22 123.71 42.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.286 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.5 t -149.29 144.15 26.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.509 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 16.0 mmt180 . . . . . 0 C--O 1.22 -0.5 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.555 179.971 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 5.1 mm100 . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.87 0.366 . . . . 0.0 110.589 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.2 t90 -67.88 129.01 38.6 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.762 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 76.3 m -121.84 129.37 52.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.374 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.587 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 1.0 OUTLIER -53.61 154.37 6.71 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.466 -179.577 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -64.75 146.57 88.7 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 121.617 1.545 . . . . 0.0 110.985 179.46 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 91.8 -7.95 78.79 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 110.154 -1.178 . . . . 0.0 110.154 -178.617 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.6 m-85 -109.51 147.51 32.8 Favored 'General case' 0 C--N 1.333 -0.12 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.266 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -126.17 136.1 52.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.941 0.4 . . . . 0.0 111.126 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 92.8 t80 -60.05 131.34 50.54 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.997 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -115.59 114.17 42.46 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.884 179.088 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -72.26 -30.76 12.6 Favored 'Trans proline' 0 C--N 1.315 -1.189 0 C-N-CA 121.217 1.278 . . . . 0.0 111.452 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.13 -45.22 97.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.361 178.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 82.4 mt -85.36 -22.08 28.6 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.442 -179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.64 -0.5 89.55 Favored Glycine 0 CA--C 1.53 0.999 0 CA-C-N 116.131 -0.486 . . . . 0.0 112.16 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -141.05 176.56 4.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.734 179.703 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 93.0 m -88.05 139.89 30.05 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.02 0.438 . . . . 0.0 111.149 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.5 p -129.15 156.7 43.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.962 179.605 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt -67.76 148.43 11.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.246 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 76.6 p -128.82 153.69 47.17 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.312 179.738 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -134.66 -23.07 1.63 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.455 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.474 ' O ' ' CB ' ' A' ' 22' ' ' ARG . 66.0 m -127.14 149.26 50.04 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.524 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . 0.474 ' CB ' ' O ' ' A' ' 21' ' ' SER . 5.3 tpp85 . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 117.916 -1.04 . . . . 0.0 110.501 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 71.1 tp60 . . . . . 0 C--O 1.232 0.169 0 CA-C-O 120.642 0.258 . . . . 0.0 110.461 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.2 t90 -107.99 129.53 55.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.711 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 73.5 m -114.96 149.41 37.38 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.327 179.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.669 ' H ' ' NE2' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -72.26 162.69 72.44 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.76 179.407 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -64.96 138.98 59.62 Favored 'Trans proline' 0 C--N 1.302 -1.906 0 C-N-CA 121.734 1.623 . . . . 0.0 110.767 179.43 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.34 -6.9 83.04 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 -178.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 26.2 m-85 -112.73 144.24 42.59 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 179.699 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.92 133.76 55.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.35 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.0 t80 -63.82 130.67 45.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.938 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.04 112.09 50.23 Favored Pre-proline 0 CA--C 1.532 0.273 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.449 179.306 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -74.05 -32.19 7.2 Favored 'Trans proline' 0 C--N 1.317 -1.1 0 C-N-CA 121.397 1.398 . . . . 0.0 111.367 -179.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.8 -44.89 96.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.547 179.296 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 76.8 mt -83.38 -22.51 32.74 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.197 -179.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.18 2.3 90.47 Favored Glycine 0 CA--C 1.53 0.975 0 CA-C-N 116.151 -0.477 . . . . 0.0 112.617 179.003 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.2 179.72 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-N 117.308 0.554 . . . . 0.0 111.073 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 59.7 m -88.33 137.13 32.6 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.813 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.6 p -128.18 156.75 42.42 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-O 121.038 0.447 . . . . 0.0 110.826 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.0 tt -80.46 142.47 13.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.553 -179.109 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 77.1 p -106.3 8.47 31.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.232 0.539 . . . . 0.0 110.966 -179.647 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 61.4 tp -107.32 123.33 48.18 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.166 -0.925 . . . . 0.0 110.457 -179.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.3 t -149.98 143.9 25.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.421 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 66.1 ttp85 . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.569 179.923 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 7.5 tp-100 . . . . . 0 C--O 1.23 0.068 0 CA-C-O 120.925 0.393 . . . . 0.0 110.441 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.8 t90 -66.54 133.22 49.91 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.709 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 71.2 m -118.9 150.51 39.76 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.47 179.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.654 ' H ' ' NE2' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -73.49 162.03 76.21 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.718 179.243 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -66.04 138.29 51.72 Favored 'Trans proline' 0 C--N 1.304 -1.812 0 C-N-CA 121.772 1.648 . . . . 0.0 110.77 179.401 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.54 -7.35 82.09 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 -179.02 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 21.3 m-85 -112.04 142.68 44.17 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 179.565 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.41 133.94 54.22 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.558 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.52 130.79 45.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.913 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -114.14 112.99 46.62 Favored Pre-proline 0 CA--C 1.533 0.289 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.272 179.099 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -73.78 -32.79 7.05 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 C-N-CA 121.301 1.334 . . . . 0.0 111.454 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 63.6 t -64.27 -45.66 95.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.497 179.361 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.1 mt -81.38 -24.66 36.86 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.395 -179.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.01 1.53 88.72 Favored Glycine 0 CA--C 1.532 1.151 0 CA-C-N 116.189 -0.46 . . . . 0.0 112.595 179.139 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -139.1 179.31 3.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 117.47 0.635 . . . . 0.0 111.043 179.614 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 37.4 m -88.97 135.58 33.47 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 109.878 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.7 p -127.65 154.59 45.09 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-O 121.005 0.431 . . . . 0.0 110.805 -179.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.3 tt -72.03 153.97 7.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.459 -179.35 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 72.3 p -132.2 148.69 52.47 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.772 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 85.0 mt -140.45 145.99 37.67 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.611 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 98.9 p -64.03 -23.47 67.35 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.658 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 78.2 ttt-85 . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 117.968 -1.015 . . . . 0.0 110.58 -179.948 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 25.5 pt20 . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.859 0.361 . . . . 0.0 110.496 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.7 t90 -65.71 134.14 52.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.906 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.1 m -115.93 149.61 38.46 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.252 179.687 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.648 ' H ' ' NE2' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -75.64 162.31 72.82 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.975 179.504 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -65.68 139.54 58.4 Favored 'Trans proline' 0 C--N 1.303 -1.848 0 C-N-CA 121.77 1.647 . . . . 0.0 110.779 179.213 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.3 -7.55 81.78 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.154 -1.179 . . . . 0.0 110.154 -178.807 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 26.1 m-85 -112.37 143.93 42.66 Favored 'General case' 0 N--CA 1.462 0.157 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.2 134.22 54.68 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.551 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 86.9 t80 -63.4 130.97 46.7 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.891 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -114.56 112.07 46.01 Favored Pre-proline 0 CA--C 1.534 0.344 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.337 179.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -73.88 -32.32 7.36 Favored 'Trans proline' 0 C--N 1.316 -1.134 0 C-N-CA 121.338 1.359 . . . . 0.0 111.413 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.5 t -64.71 -45.07 96.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.684 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 76.8 mt -83.06 -22.65 33.44 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.117 -179.573 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.25 2.66 90.37 Favored Glycine 0 CA--C 1.53 0.974 0 CA-C-N 116.168 -0.469 . . . . 0.0 112.51 179.013 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.68 179.54 3.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 117.209 0.505 . . . . 0.0 111.07 179.979 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 38.3 m -88.78 134.94 33.77 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.2 p -126.55 154.46 43.83 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 121.012 0.434 . . . . 0.0 110.73 -179.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.2 tt -72.03 155.52 7.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.791 -179.158 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 76.1 p -129.19 157.81 40.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.162 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 1.4 pp -130.11 -16.87 3.54 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.695 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 40.6 t -63.12 139.36 58.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.515 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 66.9 ttp85 . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.496 -179.97 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 4.9 pp0? . . . . . 0 C--O 1.231 0.081 0 CA-C-O 120.759 0.314 . . . . 0.0 110.591 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.6 t90 -138.29 131.62 30.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.869 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.0 m -120.5 149.64 42.1 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.102 0.477 . . . . 0.0 110.544 179.335 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.441 ' NE2' ' CZ ' ' A' ' 7' ' ' TYR . 4.2 pt20 -69.14 158.74 85.75 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.124 179.679 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -55.46 137.69 78.29 Favored 'Trans proline' 0 N--CA 1.499 1.801 0 C-N-CA 121.533 1.488 . . . . 0.0 112.028 179.513 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 87.13 2.36 83.55 Favored Glycine 0 CA--C 1.53 1.018 0 N-CA-C 111.783 -0.527 . . . . 0.0 111.783 179.39 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . 0.441 ' CZ ' ' NE2' ' A' ' 4' ' ' GLN . 38.6 m-85 -120.29 143.61 48.25 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.743 0.306 . . . . 0.0 110.559 179.603 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -111.42 130.1 55.81 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.922 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -63.87 130.96 46.25 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.865 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -112.24 112.99 51.83 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.108 179.214 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -73.35 -31.81 8.79 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.266 1.31 . . . . 0.0 111.487 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.3 t -64.59 -45.89 94.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.363 179.13 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.0 mt -82.25 -27.14 32.63 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.365 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.67 3.69 90.4 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.415 -0.674 . . . . 0.0 111.415 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.416 ' C ' ' CD1' ' A' ' 15' ' ' ILE . 2.4 pp -133.46 173.03 15.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-O 120.878 0.37 . . . . 0.0 110.923 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 69.0 m -88.33 136.38 33.01 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.065 -179.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.2 p -126.39 151.26 47.89 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-O 120.958 0.408 . . . . 0.0 110.628 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.3 tt -72.88 152.29 7.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.563 -179.078 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 59.4 p -131.93 149.3 52.48 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 179.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.8 mt -140.04 146.87 39.55 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.575 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 98.7 p -63.42 -23.09 67.25 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.506 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 60.2 ttp180 . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.455 179.992 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.889 0.376 . . . . 0.0 110.609 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.8 t90 -66.45 132.03 47.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.738 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.9 m -118.54 150.24 39.97 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.429 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.66 ' H ' ' NE2' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -72.55 162.39 74.34 Favored Pre-proline 0 C--N 1.325 -0.464 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.729 179.276 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -65.12 138.94 58.68 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 C-N-CA 121.663 1.576 . . . . 0.0 110.831 179.241 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.1 -6.61 83.46 Favored Glycine 0 CA--C 1.529 0.93 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -178.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -113.28 143.6 44.14 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 179.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.25 133.89 54.86 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.423 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 89.2 t80 -63.48 131.03 46.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.045 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -113.98 112.12 47.59 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.404 179.288 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -73.99 -32.13 7.36 Favored 'Trans proline' 0 C--N 1.316 -1.147 0 C-N-CA 121.349 1.366 . . . . 0.0 111.458 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.68 -45.13 96.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.573 179.215 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 77.7 mt -82.63 -22.77 34.6 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.254 -179.726 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.35 2.37 90.28 Favored Glycine 0 CA--C 1.529 0.955 0 CA-C-N 116.086 -0.506 . . . . 0.0 112.574 179.195 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.98 179.43 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.172 0 CA-C-N 117.209 0.504 . . . . 0.0 111.027 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.4 m -88.81 136.3 33.07 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.774 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.9 p -127.66 156.22 42.68 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-O 120.98 0.419 . . . . 0.0 110.816 -179.783 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.8 tt -78.95 142.86 13.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.495 -179.258 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 75.4 p -105.2 7.88 33.8 Favored 'General case' 0 CA--C 1.519 -0.219 0 CA-C-O 121.285 0.564 . . . . 0.0 111.004 -179.679 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 61.3 tp -108.43 123.02 48.21 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.186 -0.916 . . . . 0.0 110.3 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 69.0 m -68.79 147.66 51.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.66 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 39.7 ttm105 . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.556 179.827 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 5.5 tm0? . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.784 0.326 . . . . 0.0 110.382 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.0 t90 -139.77 131.4 27.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.774 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 73.0 m -119.18 148.73 42.77 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.367 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.563 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -69.89 159.25 84.85 Favored Pre-proline 0 C--N 1.327 -0.401 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.613 179.072 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -63.18 139.58 73.14 Favored 'Trans proline' 0 C--N 1.302 -1.892 0 C-N-CA 121.631 1.554 . . . . 0.0 111.035 179.642 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 90.3 -6.46 82.44 Favored Glycine 0 CA--C 1.529 0.911 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 -178.885 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 29.9 m-85 -114.79 144.35 43.64 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.666 0.269 . . . . 0.0 110.406 179.754 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.59 133.3 54.7 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.243 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.28 131.16 47.44 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.857 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.89 112.22 47.79 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.504 179.345 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -74.38 -31.74 7.05 Favored 'Trans proline' 0 C--N 1.317 -1.112 0 C-N-CA 121.374 1.383 . . . . 0.0 111.271 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.1 t -64.67 -44.94 96.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.47 179.198 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 76.9 mt -83.8 -22.51 31.78 Favored 'General case' 0 CA--C 1.529 0.154 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.262 -179.572 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.44 2.14 90.19 Favored Glycine 0 CA--C 1.531 1.042 0 CA-C-N 116.199 -0.455 . . . . 0.0 112.573 179.125 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.07 -179.11 2.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 117.214 0.507 . . . . 0.0 111.018 179.937 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.7 m -90.8 134.96 34.04 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.177 -0.465 . . . . 0.0 109.84 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 78.5 p -127.1 153.28 46.2 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-O 120.95 0.405 . . . . 0.0 110.877 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.3 tt -72.22 154.22 7.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.652 -179.16 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 60.0 p -128.73 157.35 41.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.242 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 59.9 tp -135.73 -89.24 0.32 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.365 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 97.5 p -64.6 -23.73 67.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.593 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 40.2 ptt180 . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.657 -179.925 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 64.1 tt0 . . . . . 0 C--O 1.232 0.17 0 CA-C-O 120.794 0.331 . . . . 0.0 110.566 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 92.2 t90 -67.25 132.26 47.39 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.769 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 71.4 m -118.01 149.88 40.21 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.203 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.65 ' H ' ' NE2' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -72.73 161.98 76.54 Favored Pre-proline 0 C--N 1.325 -0.493 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.75 179.431 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -65.8 138.48 53.51 Favored 'Trans proline' 0 C--N 1.302 -1.901 0 C-N-CA 121.699 1.6 . . . . 0.0 110.846 179.399 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.5 -7.15 82.52 Favored Glycine 0 CA--C 1.527 0.798 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 -178.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -112.12 143.05 43.8 Favored 'General case' 0 C--N 1.332 -0.162 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.63 133.86 54.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.629 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 84.3 t80 -63.2 130.48 44.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.808 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.18 112.22 49.77 Favored Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.347 179.203 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -73.84 -32.11 7.63 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.282 1.322 . . . . 0.0 111.369 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 63.7 t -64.4 -45.07 96.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.505 179.136 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 78.4 mt -83.6 -23.53 31.86 Favored 'General case' 0 CA--C 1.529 0.161 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.294 -179.561 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.09 1.63 89.59 Favored Glycine 0 CA--C 1.53 0.995 0 CA-C-N 116.35 -0.386 . . . . 0.0 112.569 178.992 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.15 177.41 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 117.347 0.574 . . . . 0.0 110.975 179.727 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.3 m -87.76 135.27 33.45 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.5 p -127.51 154.47 45.1 Favored 'General case' 0 N--CA 1.462 0.146 0 CA-C-O 120.926 0.393 . . . . 0.0 110.853 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.6 tt -72.02 153.25 7.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.457 -179.397 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 68.2 p -131.55 148.65 52.64 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.0 mt -141.18 145.46 35.7 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.619 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 83.7 p -71.21 160.82 32.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.449 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 83.7 mtt85 . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.979 -1.01 . . . . 0.0 110.608 179.901 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . 0.606 ' NE2' ' HH ' ' A' ' 9' ' ' TYR . 98.1 mt-30 . . . . . 0 C--O 1.231 0.114 0 CA-C-O 121.07 0.462 . . . . 0.0 110.349 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.0 t90 -69.96 132.6 46.2 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.936 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 77.9 m -116.02 138.05 51.57 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.24 179.698 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.57 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 3.9 pm0 -72.61 158.78 86.8 Favored Pre-proline 0 CA--C 1.535 0.391 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.772 179.833 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_exo -54.32 140.01 73.11 Favored 'Trans proline' 0 N--CA 1.497 1.727 0 C-N-CA 121.23 1.287 . . . . 0.0 111.568 179.194 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 90.81 -8.63 79.52 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.737 -0.945 . . . . 0.0 110.737 -179.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 33.1 m-85 -117.16 140.35 49.63 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 110.273 -0.269 . . . . 0.0 110.273 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.99 133.76 54.8 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.349 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.606 ' HH ' ' NE2' ' A' ' 1' ' ' GLN . 88.2 t80 -62.44 131.47 49.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.921 -179.768 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -114.07 112.26 47.26 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.393 179.028 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -73.61 -31.79 8.36 Favored 'Trans proline' 0 N--CA 1.487 1.103 0 C-N-CA 121.373 1.382 . . . . 0.0 111.404 -179.682 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.0 t -64.93 -44.85 96.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.412 179.333 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 77.0 mt -83.85 -23.64 31.25 Favored 'General case' 0 CA--C 1.53 0.189 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.27 -179.602 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.84 1.62 89.84 Favored Glycine 0 CA--C 1.531 1.077 0 CA-C-N 116.073 -0.512 . . . . 0.0 112.53 179.027 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.16 177.85 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 117.349 0.575 . . . . 0.0 111.056 179.807 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 63.1 m -86.29 137.26 32.74 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.13 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.6 p -128.15 154.37 45.85 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-O 120.797 0.332 . . . . 0.0 110.746 179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.5 tt -74.66 151.57 6.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.585 -179.202 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 68.2 p -129.8 155.42 46.0 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.1 179.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 60.0 tp -119.45 -38.12 3.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.202 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 93.8 p -153.05 161.83 42.04 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.489 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 78.1 ttt-85 . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.993 -1.004 . . . . 0.0 110.531 -179.945 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 22.0 mp0 . . . . . 0 C--O 1.232 0.162 0 CA-C-O 120.824 0.345 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.7 t90 -67.69 128.95 38.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.716 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 79.8 m -120.73 128.06 52.58 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.393 179.781 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.598 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 1.0 OUTLIER -53.12 154.37 5.53 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.536 -179.46 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo -64.39 146.97 90.63 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 121.574 1.516 . . . . 0.0 111.024 179.597 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 92.06 -7.9 78.3 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 -178.519 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 28.6 m-85 -109.89 146.58 34.9 Favored 'General case' 0 C--O 1.233 0.189 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 179.181 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -124.92 135.39 52.8 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.936 0.398 . . . . 0.0 111.151 -179.469 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -60.29 131.19 50.02 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.113 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.4 114.17 48.02 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.696 178.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -71.82 -30.34 14.36 Favored 'Trans proline' 0 C--N 1.316 -1.164 0 C-N-CA 121.304 1.336 . . . . 0.0 111.525 -179.539 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.3 t -64.2 -45.42 96.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.141 178.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.0 mt -85.43 -24.43 27.47 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.436 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.21 0.89 90.16 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 -179.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.414 ' C ' ' CD1' ' A' ' 15' ' ' ILE . 2.5 pp -135.66 171.16 17.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 120.661 0.267 . . . . 0.0 110.557 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 96.7 m -88.06 141.23 28.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.975 0.417 . . . . 0.0 111.015 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.8 p -128.99 157.05 42.77 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.116 179.465 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt -69.62 147.24 11.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.446 -179.545 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 75.4 p -127.38 153.19 46.53 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.306 179.634 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.579 ' CD1' ' N ' ' A' ' 20' ' ' LEU . 0.0 OUTLIER -141.65 170.72 15.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.141 0.496 . . . . 0.0 111.027 179.983 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 68.2 m -71.9 148.39 46.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.581 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 84.4 mtp180 . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.65 179.903 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 7.3 tp-100 . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.922 0.392 . . . . 0.0 110.4 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 92.0 t90 -67.66 132.58 47.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.79 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.8 m -117.57 150.67 38.6 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.216 179.608 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.653 ' H ' ' NE2' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -73.89 162.02 75.96 Favored Pre-proline 0 C--N 1.325 -0.473 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.908 179.446 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -65.7 138.68 54.77 Favored 'Trans proline' 0 C--N 1.302 -1.887 0 C-N-CA 121.799 1.666 . . . . 0.0 110.757 179.398 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.62 -7.2 82.35 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 -178.836 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.0 m-85 -112.57 143.35 43.89 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 179.506 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -114.12 133.9 55.25 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.598 -179.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 85.6 t80 -62.94 131.02 47.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.917 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -113.96 112.77 47.26 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.262 179.222 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -73.39 -32.52 7.98 Favored 'Trans proline' 0 C--N 1.316 -1.182 0 C-N-CA 121.34 1.36 . . . . 0.0 111.436 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 64.7 t -64.86 -45.29 95.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.653 179.274 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 81.5 mt -81.91 -24.34 35.7 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.363 -179.67 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.21 1.51 89.51 Favored Glycine 0 CA--C 1.531 1.051 0 CA-C-N 116.214 -0.448 . . . . 0.0 112.639 179.122 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.401 HG22 HD12 ' A' ' 15' ' ' ILE . 0.0 OUTLIER -139.06 176.9 5.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 117.366 0.583 . . . . 0.0 111.032 179.67 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 38.8 m -85.78 135.25 33.81 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.6 p -127.95 155.26 44.52 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-O 120.978 0.418 . . . . 0.0 110.845 -179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.3 tt -74.0 154.45 6.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.582 -179.348 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 58.7 p -128.89 156.56 43.49 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.293 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.56 ' CD2' ' N ' ' A' ' 20' ' ' LEU . 1.4 pt? -155.78 159.17 39.22 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.7 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 83.2 p -70.97 160.33 33.09 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.497 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 82.4 mtp180 . . . . . 0 C--O 1.219 -0.511 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.529 179.975 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . 0.543 ' NE2' ' HH ' ' A' ' 9' ' ' TYR . 96.8 mt-30 . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.722 0.296 . . . . 0.0 110.651 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.8 t90 -140.73 134.37 30.2 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.631 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 77.2 m -118.69 149.98 40.52 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.662 179.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.656 ' H ' ' NE2' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -73.92 162.5 73.76 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 115.815 -0.629 . . . . 0.0 109.853 179.263 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -65.1 138.73 57.85 Favored 'Trans proline' 0 C--N 1.302 -1.911 0 C-N-CA 121.637 1.558 . . . . 0.0 110.703 179.343 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.56 -7.35 82.08 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 -178.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.9 m-85 -112.97 144.72 42.06 Favored 'General case' 0 N--CA 1.462 0.138 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 179.678 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.93 133.89 55.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.548 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.543 ' HH ' ' NE2' ' A' ' 1' ' ' GLN . 90.3 t80 -63.66 130.92 46.27 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.82 179.988 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.28 112.27 49.46 Favored Pre-proline 0 CA--C 1.533 0.301 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.403 179.349 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -74.21 -31.99 7.12 Favored 'Trans proline' 0 C--N 1.317 -1.108 0 C-N-CA 121.399 1.399 . . . . 0.0 111.337 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.9 t -64.5 -45.01 96.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.513 179.216 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 74.9 mt -83.66 -22.75 32.05 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.325 -179.351 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.39 2.47 90.22 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-N 116.245 -0.434 . . . . 0.0 112.456 179.115 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.23 -179.87 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-N 117.23 0.515 . . . . 0.0 111.07 179.962 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 59.1 m -90.3 135.56 33.6 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.953 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.5 p -127.89 154.46 45.48 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 120.98 0.419 . . . . 0.0 110.792 179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.7 tt -72.88 154.61 7.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.568 -179.342 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 70.6 p -128.48 157.53 40.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.364 179.862 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.574 ' CD2' ' N ' ' A' ' 20' ' ' LEU . 1.5 pt? -152.01 162.36 41.21 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.694 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.0 t -60.92 -44.6 96.98 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.459 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 117.876 -1.059 . . . . 0.0 110.484 179.917 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 4.9 mm100 . . . . . 0 C--O 1.232 0.173 0 CA-C-O 120.724 0.297 . . . . 0.0 110.543 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.1 t90 -67.75 128.98 38.48 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.765 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 82.0 m -121.38 128.4 52.18 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.405 179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.584 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 1.3 pm0 -53.79 154.19 7.38 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.499 -179.504 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -64.5 147.26 90.37 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 121.548 1.499 . . . . 0.0 110.853 179.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 92.39 -7.4 77.96 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -178.383 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 32.6 m-85 -112.04 145.98 38.72 Favored 'General case' 0 C--N 1.333 -0.116 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 179.265 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -124.13 135.86 53.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.083 0.468 . . . . 0.0 111.137 -179.257 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 89.8 t80 -60.34 131.51 51.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.196 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.99 114.43 46.34 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.61 178.829 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -71.93 -30.76 13.49 Favored 'Trans proline' 0 C--N 1.315 -1.188 0 C-N-CA 121.255 1.303 . . . . 0.0 111.708 -179.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.2 t -64.26 -45.45 96.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.264 178.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.7 mt -84.54 -24.76 29.16 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.409 -179.818 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.34 0.74 90.09 Favored Glycine 0 CA--C 1.527 0.831 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.42 ' C ' ' CD1' ' A' ' 15' ' ' ILE . 2.5 pp -135.26 171.68 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.597 0.237 . . . . 0.0 110.463 179.806 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 92.4 m -88.79 140.94 28.93 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.073 0.464 . . . . 0.0 110.976 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.8 p -128.41 155.92 43.98 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.838 179.506 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.4 tt -67.43 143.3 15.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.139 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.7 t -144.86 146.66 32.16 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.606 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.583 ' CD2' ' N ' ' A' ' 20' ' ' LEU . 0.3 OUTLIER -132.22 36.2 3.64 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.438 -179.702 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 40.8 t -63.49 139.7 58.8 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.432 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 43.5 ttm180 . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.534 -179.977 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 79.1 mt-30 . . . . . 0 C--O 1.232 0.154 0 CA-C-O 120.941 0.4 . . . . 0.0 110.391 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.1 t90 -70.54 133.89 47.19 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.938 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 70.8 m -118.17 148.35 42.45 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.389 179.672 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLN . . . . . 0.579 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -73.56 158.49 86.32 Favored Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.638 179.032 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -61.58 140.32 86.27 Favored 'Trans proline' 0 C--N 1.304 -1.783 0 C-N-CA 121.629 1.553 . . . . 0.0 111.056 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 91.25 -8.39 79.4 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 -178.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 46.9 m-85 -113.94 142.07 46.6 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 120.648 0.261 . . . . 0.0 110.426 179.576 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -110.24 132.49 54.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.082 179.474 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -64.03 131.64 48.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.012 -179.637 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -112.73 113.63 50.09 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.122 178.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -73.3 -32.71 7.93 Favored 'Trans proline' 0 C--N 1.316 -1.144 0 C-N-CA 121.257 1.305 . . . . 0.0 111.598 -179.646 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.3 t -64.38 -46.03 94.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.529 179.262 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.6 mt -81.54 -27.07 34.55 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.303 -179.942 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.73 2.99 90.69 Favored Glycine 0 CA--C 1.528 0.845 0 N-CA-C 111.342 -0.703 . . . . 0.0 111.342 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ILE . . . . . 0.422 ' C ' ' CD1' ' A' ' 15' ' ' ILE . 2.4 pp -133.03 173.44 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.173 0 CA-C-O 120.865 0.364 . . . . 0.0 110.689 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 48.3 m -87.8 136.89 32.76 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.039 -179.578 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.3 p -128.55 154.23 46.38 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 121.372 0.606 . . . . 0.0 111.287 -179.881 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.412 HG23 HD12 ' A' ' 18' ' ' ILE . 0.4 OUTLIER -72.86 141.79 15.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.223 -0.898 . . . . 0.0 110.462 -179.877 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 11.2 t -144.76 149.46 35.56 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.248 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' LEU . . . . . 0.577 ' CD2' ' N ' ' A' ' 20' ' ' LEU . 1.5 pt? -151.95 165.12 35.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.941 -179.826 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.1 t -61.09 -43.53 98.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.923 -179.776 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 60.1 ttt85 . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.995 -1.002 . . . . 0.0 110.394 -179.627 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.689 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 35.0 m-85 -118.68 141.27 48.77 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.777 0.322 . . . . 0.0 110.549 179.715 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.81 133.02 55.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.215 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 91.5 t80 -63.83 131.23 47.14 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.072 -179.667 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -111.71 112.87 53.36 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.972 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -73.25 -32.08 8.68 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 C-N-CA 121.269 1.313 . . . . 0.0 111.465 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 63.6 t -64.65 -45.62 94.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.47 179.096 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 83.3 mt -82.85 -27.19 30.97 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.392 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.68 3.33 90.55 Favored Glycine 0 CA--C 1.528 0.88 0 N-CA-C 111.367 -0.693 . . . . 0.0 111.367 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.614 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.4 pp -133.18 172.73 15.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 120.812 0.339 . . . . 0.0 110.805 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 83.8 m -87.71 137.92 31.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.203 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.0 p -127.6 153.62 46.2 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.922 0.391 . . . . 0.0 110.504 179.6 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.5 tt . . . . . 0 C--N 1.328 -0.364 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.559 -179.069 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.819 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.5 m-85 -112.64 143.84 43.15 Favored 'General case' 0 C--N 1.333 -0.119 0 N-CA-C 110.217 -0.29 . . . . 0.0 110.217 179.672 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.3 133.92 54.87 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.607 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 91.7 t80 -64.22 131.72 48.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.854 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -112.37 113.4 51.22 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.073 178.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -73.39 -32.46 8.03 Favored 'Trans proline' 0 N--CA 1.487 1.144 0 C-N-CA 121.294 1.33 . . . . 0.0 111.628 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.0 t -64.57 -45.86 94.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.422 179.305 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.447 HD12 HG21 ' A' ' 17' ' ' THR . 85.3 mt -81.19 -26.61 35.83 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.352 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.58 3.07 90.67 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 111.289 -0.724 . . . . 0.0 111.289 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.617 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.4 pp -134.15 173.18 15.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 120.913 0.387 . . . . 0.0 110.771 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 58.2 m -87.93 136.73 32.83 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.132 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.447 HG21 HD12 ' A' ' 13' ' ' LEU . 82.0 p -127.58 154.85 44.71 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-O 120.978 0.418 . . . . 0.0 110.713 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.4 tt . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.541 -179.355 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.841 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.5 m-85 -112.27 141.72 45.64 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 120.701 0.286 . . . . 0.0 110.377 179.62 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -110.82 133.27 53.5 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.447 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 91.9 t80 -63.83 131.42 47.72 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.862 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -112.87 113.11 50.06 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.048 179.01 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -73.43 -32.06 8.39 Favored 'Trans proline' 0 C--N 1.316 -1.161 0 C-N-CA 121.302 1.334 . . . . 0.0 111.607 -179.739 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.7 t -64.41 -45.89 94.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.412 179.117 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.405 HD12 HG21 ' A' ' 17' ' ' THR . 85.0 mt -81.84 -26.54 34.2 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.262 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.66 3.29 90.57 Favored Glycine 0 CA--C 1.527 0.802 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.617 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.4 pp -134.2 172.98 15.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 120.857 0.361 . . . . 0.0 110.786 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.8 m -88.49 137.68 32.11 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.265 -0.425 . . . . 0.0 109.862 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.405 HG21 HD12 ' A' ' 13' ' ' LEU . 81.3 p -127.65 155.28 44.16 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.978 0.418 . . . . 0.0 110.777 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.8 tt . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.354 -179.371 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.801 0 N-CA-C 110.066 -1.214 . . . . 0.0 110.066 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.2 m-85 -108.47 145.77 34.17 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 179.308 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -123.26 134.83 54.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.1 -179.511 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -60.43 131.13 49.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.068 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.64 114.04 47.46 Favored Pre-proline 0 CA--C 1.533 0.299 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.739 179.052 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -72.22 -30.37 13.16 Favored 'Trans proline' 0 C--N 1.315 -1.192 0 C-N-CA 121.363 1.376 . . . . 0.0 111.49 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.5 t -64.04 -45.56 96.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.094 178.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 85.4 mt -84.83 -24.48 28.61 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.293 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.43 0.67 90.08 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.627 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.5 pp -136.23 170.87 17.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.699 0.285 . . . . 0.0 110.618 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 93.9 m -87.57 141.2 28.79 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.908 0.385 . . . . 0.0 110.92 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.9 p -129.06 156.97 43.0 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.111 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.4 tt . . . . . 0 C--N 1.327 -0.388 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.254 -179.742 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.716 0 N-CA-C 110.057 -1.217 . . . . 0.0 110.057 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 27.4 m-85 -108.99 146.75 33.36 Favored 'General case' 0 C--N 1.332 -0.164 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.296 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -125.01 135.61 52.93 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.031 0.443 . . . . 0.0 111.076 -179.365 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -60.47 131.57 51.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.123 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.86 114.31 46.75 Favored Pre-proline 0 CA--C 1.534 0.36 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.725 179.032 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -71.92 -30.45 13.92 Favored 'Trans proline' 0 C--N 1.315 -1.203 0 C-N-CA 121.329 1.353 . . . . 0.0 111.594 -179.455 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.9 t -64.13 -45.45 96.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.085 178.932 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.6 mt -85.3 -24.65 27.61 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.389 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.32 0.9 90.23 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.63 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.5 pp -135.82 171.1 17.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.682 0.277 . . . . 0.0 110.464 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 99.1 m -87.94 140.97 28.96 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.875 0.369 . . . . 0.0 110.954 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.2 p -128.89 156.96 42.86 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.932 179.645 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt . . . . . 0 C--N 1.328 -0.358 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.382 -179.548 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.768 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 26.4 m-85 -108.42 146.12 33.57 Favored 'General case' 0 C--N 1.332 -0.154 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 179.215 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -123.89 135.43 53.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.953 0.406 . . . . 0.0 111.144 -179.481 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.8 t80 -60.45 131.61 51.29 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.041 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -114.03 114.21 46.33 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.769 179.017 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -71.93 -30.5 13.84 Favored 'Trans proline' 0 C--N 1.316 -1.136 0 C-N-CA 121.388 1.392 . . . . 0.0 111.552 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.2 t -64.16 -45.62 95.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.208 179.019 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.42 HD12 HG21 ' A' ' 17' ' ' THR . 84.7 mt -84.86 -24.41 28.58 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.423 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.31 0.86 90.19 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.628 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.5 pp -135.91 171.34 17.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 120.668 0.27 . . . . 0.0 110.557 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 99.1 m -87.98 141.21 28.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.946 0.403 . . . . 0.0 110.792 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.42 HG21 HD12 ' A' ' 13' ' ' LEU . 76.9 p -129.01 157.09 42.67 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.074 179.807 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.2 tt . . . . . 0 C--N 1.327 -0.371 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.311 -179.632 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.777 0 N-CA-C 110.154 -1.178 . . . . 0.0 110.154 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.6 m-85 -109.51 147.51 32.8 Favored 'General case' 0 C--N 1.333 -0.12 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.266 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -126.17 136.1 52.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.941 0.4 . . . . 0.0 111.126 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 92.8 t80 -60.05 131.34 50.54 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.997 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -115.59 114.17 42.46 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.884 179.088 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -72.26 -30.76 12.6 Favored 'Trans proline' 0 C--N 1.315 -1.189 0 C-N-CA 121.217 1.278 . . . . 0.0 111.452 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.13 -45.22 97.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.361 178.909 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.425 HD12 HG21 ' A' ' 17' ' ' THR . 82.4 mt -85.36 -22.08 28.6 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.442 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.64 -0.5 89.55 Favored Glycine 0 CA--C 1.53 0.999 0 CA-C-N 116.131 -0.486 . . . . 0.0 112.16 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -141.05 176.56 4.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.734 179.703 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 93.0 m -88.05 139.89 30.05 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.02 0.438 . . . . 0.0 111.149 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.425 HG21 HD12 ' A' ' 13' ' ' LEU . 80.5 p -129.15 156.7 43.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.962 179.605 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt . . . . . 0 C--N 1.327 -0.411 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.246 -179.658 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.825 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 26.2 m-85 -112.73 144.24 42.59 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 179.699 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.92 133.76 55.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.35 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.0 t80 -63.82 130.67 45.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.938 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.04 112.09 50.23 Favored Pre-proline 0 CA--C 1.532 0.273 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.449 179.306 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -74.05 -32.19 7.2 Favored 'Trans proline' 0 C--N 1.317 -1.1 0 C-N-CA 121.397 1.398 . . . . 0.0 111.367 -179.786 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.8 -44.89 96.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.547 179.296 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.539 HD12 HG21 ' A' ' 17' ' ' THR . 76.8 mt -83.38 -22.51 32.74 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.197 -179.657 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.18 2.3 90.47 Favored Glycine 0 CA--C 1.53 0.975 0 CA-C-N 116.151 -0.477 . . . . 0.0 112.617 179.003 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.2 179.72 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-N 117.308 0.554 . . . . 0.0 111.073 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 59.7 m -88.33 137.13 32.6 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.813 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.539 HG21 HD12 ' A' ' 13' ' ' LEU . 82.6 p -128.18 156.75 42.42 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-O 121.038 0.447 . . . . 0.0 110.826 -179.866 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.0 tt . . . . . 0 C--N 1.33 -0.241 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.553 -179.109 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.814 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 21.3 m-85 -112.04 142.68 44.17 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 179.565 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.41 133.94 54.22 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.558 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.52 130.79 45.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.913 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -114.14 112.99 46.62 Favored Pre-proline 0 CA--C 1.533 0.289 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.272 179.099 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -73.78 -32.79 7.05 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 C-N-CA 121.301 1.334 . . . . 0.0 111.454 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 63.6 t -64.27 -45.66 95.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.497 179.361 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.446 HD12 HG21 ' A' ' 17' ' ' THR . 84.1 mt -81.38 -24.66 36.86 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.395 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.01 1.53 88.72 Favored Glycine 0 CA--C 1.532 1.151 0 CA-C-N 116.189 -0.46 . . . . 0.0 112.595 179.139 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.446 HD13 ' H ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -139.1 179.31 3.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 117.47 0.635 . . . . 0.0 111.043 179.614 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 37.4 m -88.97 135.58 33.47 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 109.878 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.446 HG21 HD12 ' A' ' 13' ' ' LEU . 82.7 p -127.65 154.59 45.09 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-O 121.005 0.431 . . . . 0.0 110.805 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.3 tt . . . . . 0 C--N 1.33 -0.239 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.459 -179.35 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.711 0 N-CA-C 110.154 -1.179 . . . . 0.0 110.154 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 26.1 m-85 -112.37 143.93 42.66 Favored 'General case' 0 N--CA 1.462 0.157 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.2 134.22 54.68 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.551 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 86.9 t80 -63.4 130.97 46.7 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.891 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -114.56 112.07 46.01 Favored Pre-proline 0 CA--C 1.534 0.344 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.337 179.365 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -73.88 -32.32 7.36 Favored 'Trans proline' 0 C--N 1.316 -1.134 0 C-N-CA 121.338 1.359 . . . . 0.0 111.413 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.5 t -64.71 -45.07 96.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.684 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.59 HD12 HG21 ' A' ' 17' ' ' THR . 76.8 mt -83.06 -22.65 33.44 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.117 -179.573 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.25 2.66 90.37 Favored Glycine 0 CA--C 1.53 0.974 0 CA-C-N 116.168 -0.469 . . . . 0.0 112.51 179.013 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.401 ' C ' HD13 ' A' ' 15' ' ' ILE . 0.0 OUTLIER -138.68 179.54 3.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 117.209 0.505 . . . . 0.0 111.07 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 38.3 m -88.78 134.94 33.77 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.59 HG21 HD12 ' A' ' 13' ' ' LEU . 80.2 p -126.55 154.46 43.83 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 121.012 0.434 . . . . 0.0 110.73 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.2 tt . . . . . 0 C--N 1.328 -0.363 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.791 -179.158 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.018 0 N-CA-C 111.783 -0.527 . . . . 0.0 111.783 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -120.29 143.61 48.25 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.743 0.306 . . . . 0.0 110.559 179.603 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -111.42 130.1 55.81 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.922 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -63.87 130.96 46.25 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.865 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -112.24 112.99 51.83 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.108 179.214 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -73.35 -31.81 8.79 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.266 1.31 . . . . 0.0 111.487 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.3 t -64.59 -45.89 94.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.363 179.13 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.0 mt -82.25 -27.14 32.63 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.365 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.67 3.69 90.4 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.415 -0.674 . . . . 0.0 111.415 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.601 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.4 pp -133.46 173.03 15.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-O 120.878 0.37 . . . . 0.0 110.923 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 69.0 m -88.33 136.38 33.01 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.065 -179.77 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.2 p -126.39 151.26 47.89 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-O 120.958 0.408 . . . . 0.0 110.628 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.3 tt . . . . . 0 C--N 1.327 -0.388 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.563 -179.078 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.93 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -113.28 143.6 44.14 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 179.664 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.25 133.89 54.86 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.423 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 89.2 t80 -63.48 131.03 46.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.045 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -113.98 112.12 47.59 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.404 179.288 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -73.99 -32.13 7.36 Favored 'Trans proline' 0 C--N 1.316 -1.147 0 C-N-CA 121.349 1.366 . . . . 0.0 111.458 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.68 -45.13 96.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.573 179.215 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.556 HD12 HG21 ' A' ' 17' ' ' THR . 77.7 mt -82.63 -22.77 34.6 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.254 -179.726 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.35 2.37 90.28 Favored Glycine 0 CA--C 1.529 0.955 0 CA-C-N 116.086 -0.506 . . . . 0.0 112.574 179.195 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.98 179.43 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.172 0 CA-C-N 117.209 0.504 . . . . 0.0 111.027 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.4 m -88.81 136.3 33.07 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.774 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.556 HG21 HD12 ' A' ' 13' ' ' LEU . 81.9 p -127.66 156.22 42.68 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-O 120.98 0.419 . . . . 0.0 110.816 -179.783 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.8 tt . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.495 -179.258 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.911 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 29.9 m-85 -114.79 144.35 43.64 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.666 0.269 . . . . 0.0 110.406 179.754 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.59 133.3 54.7 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.243 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.28 131.16 47.44 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.857 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.89 112.22 47.79 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.504 179.345 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -74.38 -31.74 7.05 Favored 'Trans proline' 0 C--N 1.317 -1.112 0 C-N-CA 121.374 1.383 . . . . 0.0 111.271 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.1 t -64.67 -44.94 96.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.47 179.198 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.532 HD12 HG21 ' A' ' 17' ' ' THR . 76.9 mt -83.8 -22.51 31.78 Favored 'General case' 0 CA--C 1.529 0.154 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.262 -179.572 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.44 2.14 90.19 Favored Glycine 0 CA--C 1.531 1.042 0 CA-C-N 116.199 -0.455 . . . . 0.0 112.573 179.125 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.4 HD13 ' C ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -138.07 -179.11 2.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 117.214 0.507 . . . . 0.0 111.018 179.937 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.7 m -90.8 134.96 34.04 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.177 -0.465 . . . . 0.0 109.84 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.532 HG21 HD12 ' A' ' 13' ' ' LEU . 78.5 p -127.1 153.28 46.2 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-O 120.95 0.405 . . . . 0.0 110.877 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.3 tt . . . . . 0 C--N 1.328 -0.351 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.652 -179.16 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.798 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -112.12 143.05 43.8 Favored 'General case' 0 C--N 1.332 -0.162 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.63 133.86 54.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.629 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 84.3 t80 -63.2 130.48 44.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.808 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.18 112.22 49.77 Favored Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.347 179.203 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -73.84 -32.11 7.63 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.282 1.322 . . . . 0.0 111.369 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 63.7 t -64.4 -45.07 96.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.505 179.136 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.492 HD12 HG21 ' A' ' 17' ' ' THR . 78.4 mt -83.6 -23.53 31.86 Favored 'General case' 0 CA--C 1.529 0.161 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.294 -179.561 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.09 1.63 89.59 Favored Glycine 0 CA--C 1.53 0.995 0 CA-C-N 116.35 -0.386 . . . . 0.0 112.569 178.992 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.407 HD13 ' H ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -138.15 177.41 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 117.347 0.574 . . . . 0.0 110.975 179.727 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.3 m -87.76 135.27 33.45 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.492 HG21 HD12 ' A' ' 13' ' ' LEU . 81.5 p -127.51 154.47 45.1 Favored 'General case' 0 N--CA 1.462 0.146 0 CA-C-O 120.926 0.393 . . . . 0.0 110.853 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.6 tt . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.457 -179.397 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.724 0 N-CA-C 110.737 -0.945 . . . . 0.0 110.737 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 33.1 m-85 -117.16 140.35 49.63 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 110.273 -0.269 . . . . 0.0 110.273 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.99 133.76 54.8 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.349 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 88.2 t80 -62.44 131.47 49.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.921 -179.768 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -114.07 112.26 47.26 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.393 179.028 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -73.61 -31.79 8.36 Favored 'Trans proline' 0 N--CA 1.487 1.103 0 C-N-CA 121.373 1.382 . . . . 0.0 111.404 -179.682 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.0 t -64.93 -44.85 96.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.412 179.333 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.511 HD12 HG21 ' A' ' 17' ' ' THR . 77.0 mt -83.85 -23.64 31.25 Favored 'General case' 0 CA--C 1.53 0.189 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.27 -179.602 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.84 1.62 89.84 Favored Glycine 0 CA--C 1.531 1.077 0 CA-C-N 116.073 -0.512 . . . . 0.0 112.53 179.027 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.16 177.85 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 117.349 0.575 . . . . 0.0 111.056 179.807 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 63.1 m -86.29 137.26 32.74 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.13 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.511 HG21 HD12 ' A' ' 13' ' ' LEU . 76.6 p -128.15 154.37 45.85 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-O 120.797 0.332 . . . . 0.0 110.746 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.5 tt . . . . . 0 C--N 1.327 -0.384 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.585 -179.202 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.788 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 28.6 m-85 -109.89 146.58 34.9 Favored 'General case' 0 C--O 1.233 0.189 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 179.181 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -124.92 135.39 52.8 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.936 0.398 . . . . 0.0 111.151 -179.469 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -60.29 131.19 50.02 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.113 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.4 114.17 48.02 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.696 178.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -71.82 -30.34 14.36 Favored 'Trans proline' 0 C--N 1.316 -1.164 0 C-N-CA 121.304 1.336 . . . . 0.0 111.525 -179.539 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.3 t -64.2 -45.42 96.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.141 178.994 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.0 mt -85.43 -24.43 27.47 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.436 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.21 0.89 90.16 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 -179.822 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.629 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.5 pp -135.66 171.16 17.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 120.661 0.267 . . . . 0.0 110.557 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 96.7 m -88.06 141.23 28.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.975 0.417 . . . . 0.0 111.015 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.8 p -128.99 157.05 42.77 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.116 179.465 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt . . . . . 0 C--N 1.326 -0.432 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.446 -179.545 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.836 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.0 m-85 -112.57 143.35 43.89 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 179.506 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -114.12 133.9 55.25 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.598 -179.737 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 85.6 t80 -62.94 131.02 47.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.917 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -113.96 112.77 47.26 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.262 179.222 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -73.39 -32.52 7.98 Favored 'Trans proline' 0 C--N 1.316 -1.182 0 C-N-CA 121.34 1.36 . . . . 0.0 111.436 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 64.7 t -64.86 -45.29 95.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.653 179.274 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.529 HD12 HG21 ' A' ' 17' ' ' THR . 81.5 mt -81.91 -24.34 35.7 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.363 -179.67 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.21 1.51 89.51 Favored Glycine 0 CA--C 1.531 1.051 0 CA-C-N 116.214 -0.448 . . . . 0.0 112.639 179.122 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.42 HD13 ' H ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -139.06 176.9 5.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 117.366 0.583 . . . . 0.0 111.032 179.67 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 38.8 m -85.78 135.25 33.81 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.529 HG21 HD12 ' A' ' 13' ' ' LEU . 82.6 p -127.95 155.26 44.52 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-O 120.978 0.418 . . . . 0.0 110.845 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.3 tt . . . . . 0 C--N 1.331 -0.226 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.582 -179.348 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.825 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.9 m-85 -112.97 144.72 42.06 Favored 'General case' 0 N--CA 1.462 0.138 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 179.678 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.93 133.89 55.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.548 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -63.66 130.92 46.27 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.82 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.28 112.27 49.46 Favored Pre-proline 0 CA--C 1.533 0.301 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.403 179.349 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -74.21 -31.99 7.12 Favored 'Trans proline' 0 C--N 1.317 -1.108 0 C-N-CA 121.399 1.399 . . . . 0.0 111.337 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.9 t -64.5 -45.01 96.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.513 179.216 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.491 HD12 HG21 ' A' ' 17' ' ' THR . 74.9 mt -83.66 -22.75 32.05 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.325 -179.351 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.39 2.47 90.22 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-N 116.245 -0.434 . . . . 0.0 112.456 179.115 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.412 HD13 ' C ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -138.23 -179.87 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-N 117.23 0.515 . . . . 0.0 111.07 179.962 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 59.1 m -90.3 135.56 33.6 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.953 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.491 HG21 HD12 ' A' ' 13' ' ' LEU . 82.5 p -127.89 154.46 45.48 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 120.98 0.419 . . . . 0.0 110.792 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.7 tt . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.568 -179.342 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.735 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 32.6 m-85 -112.04 145.98 38.72 Favored 'General case' 0 C--N 1.333 -0.116 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 179.265 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -124.13 135.86 53.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.083 0.468 . . . . 0.0 111.137 -179.257 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 89.8 t80 -60.34 131.51 51.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.196 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.99 114.43 46.34 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.61 178.829 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -71.93 -30.76 13.49 Favored 'Trans proline' 0 C--N 1.315 -1.188 0 C-N-CA 121.255 1.303 . . . . 0.0 111.708 -179.396 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.2 t -64.26 -45.45 96.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.264 178.977 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.414 HD12 HG21 ' A' ' 17' ' ' THR . 84.7 mt -84.54 -24.76 29.16 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.409 -179.818 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.34 0.74 90.09 Favored Glycine 0 CA--C 1.527 0.831 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.638 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.5 pp -135.26 171.68 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.597 0.237 . . . . 0.0 110.463 179.806 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 92.4 m -88.79 140.94 28.93 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.073 0.464 . . . . 0.0 110.976 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.414 HG21 HD12 ' A' ' 13' ' ' LEU . 80.8 p -128.41 155.92 43.98 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.838 179.506 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.4 tt . . . . . 0 C--N 1.327 -0.395 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.139 -179.421 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.79 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 46.9 m-85 -113.94 142.07 46.6 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 120.648 0.261 . . . . 0.0 110.426 179.576 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -110.24 132.49 54.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.082 179.474 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -64.03 131.64 48.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.012 -179.637 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -112.73 113.63 50.09 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.122 178.911 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -73.3 -32.71 7.93 Favored 'Trans proline' 0 C--N 1.316 -1.144 0 C-N-CA 121.257 1.305 . . . . 0.0 111.598 -179.646 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.3 t -64.38 -46.03 94.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.529 179.262 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' LEU . . . . . 0.429 HD12 HG21 ' A' ' 17' ' ' THR . 84.6 mt -81.54 -27.07 34.55 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.303 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.73 2.99 90.69 Favored Glycine 0 CA--C 1.528 0.845 0 N-CA-C 111.342 -0.703 . . . . 0.0 111.342 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ILE . . . . . 0.619 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.4 pp -133.03 173.44 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.173 0 CA-C-O 120.865 0.364 . . . . 0.0 110.689 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 48.3 m -87.8 136.89 32.76 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.039 -179.578 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.429 HG21 HD12 ' A' ' 13' ' ' LEU . 82.3 p -128.55 154.23 46.38 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 121.372 0.606 . . . . 0.0 111.287 -179.881 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.325 -0.459 0 CA-C-N 115.223 -0.898 . . . . 0.0 110.462 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 67.9 mt-30 . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.82 0.343 . . . . 0.0 110.494 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.7 t90 -135.17 129.15 33.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.366 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 64.7 m -111.26 133.75 53.36 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.545 -179.739 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.668 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 6.5 pm0 -71.64 159.0 86.76 Favored Pre-proline 0 CA--C 1.536 0.441 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.34 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_exo -52.28 140.12 52.82 Favored 'Trans proline' 0 N--CA 1.498 1.751 0 C-N-CA 121.263 1.309 . . . . 0.0 111.833 179.739 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 91.75 -7.87 78.99 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -179.569 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' TYR . . . . . 0.507 ' CG ' ' NE2' ' A' ' 4' ' ' GLN . 35.0 m-85 -118.68 141.27 48.77 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.777 0.322 . . . . 0.0 110.549 179.715 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.81 133.02 55.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.215 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 91.5 t80 -63.83 131.23 47.14 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.072 -179.667 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -111.71 112.87 53.36 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.972 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -73.25 -32.08 8.68 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 C-N-CA 121.269 1.313 . . . . 0.0 111.465 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 63.6 t -64.65 -45.62 94.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.47 179.096 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 83.3 mt -82.85 -27.19 30.97 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.392 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.68 3.33 90.55 Favored Glycine 0 CA--C 1.528 0.88 0 N-CA-C 111.367 -0.693 . . . . 0.0 111.367 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.614 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.4 pp -133.18 172.73 15.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 120.812 0.339 . . . . 0.0 110.805 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 83.8 m -87.71 137.92 31.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.203 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.0 p -127.6 153.62 46.2 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.922 0.391 . . . . 0.0 110.504 179.6 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.5 tt -72.72 149.91 8.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.559 -179.069 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.6 t -149.63 148.56 29.46 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.129 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -120.29 -13.44 8.89 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.411 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 51.0 m 53.59 39.96 30.79 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.811 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 61.2 ttp180 . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.125 -0.94 . . . . 0.0 110.511 179.874 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLN . . . . . 0.425 ' OE1' ' N ' ' A' ' 1' ' ' GLN . 13.1 pm0 . . . . . 0 N--CA 1.457 -0.108 0 CA-C-O 120.817 0.341 . . . . 0.0 110.703 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.5 t90 -138.62 132.9 31.7 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.533 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 74.2 m -118.85 150.37 39.96 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.563 179.786 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.638 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -72.97 162.34 75.01 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.712 179.23 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -65.14 138.9 58.38 Favored 'Trans proline' 0 C--N 1.302 -1.916 0 C-N-CA 121.698 1.599 . . . . 0.0 110.765 179.333 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.43 -7.81 81.18 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 -178.878 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.5 m-85 -112.64 143.84 43.15 Favored 'General case' 0 C--N 1.333 -0.119 0 N-CA-C 110.217 -0.29 . . . . 0.0 110.217 179.672 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.3 133.92 54.87 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.607 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 91.7 t80 -64.22 131.72 48.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.854 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -112.37 113.4 51.22 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.073 178.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -73.39 -32.46 8.03 Favored 'Trans proline' 0 N--CA 1.487 1.144 0 C-N-CA 121.294 1.33 . . . . 0.0 111.628 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.0 t -64.57 -45.86 94.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.422 179.305 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.447 HD12 HG21 ' A' ' 17' ' ' THR . 85.3 mt -81.19 -26.61 35.83 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.352 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.58 3.07 90.67 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 111.289 -0.724 . . . . 0.0 111.289 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.617 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.4 pp -134.15 173.18 15.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 120.913 0.387 . . . . 0.0 110.771 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 58.2 m -87.93 136.73 32.83 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.132 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.447 HG21 HD12 ' A' ' 13' ' ' LEU . 82.0 p -127.58 154.85 44.71 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-O 120.978 0.418 . . . . 0.0 110.713 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.4 tt -72.98 149.08 8.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.541 -179.355 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 10.3 t -151.13 143.76 24.36 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.0 mt -129.95 144.23 51.22 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.642 -179.702 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.0 t -61.1 -44.33 97.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.955 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.608 -179.786 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 22.9 mm100 . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.87 0.367 . . . . 0.0 110.613 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.6 t90 -66.03 132.94 49.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.793 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.6 m -118.58 150.41 39.72 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.435 179.739 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.626 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -72.87 162.15 75.84 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.702 179.334 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -64.57 138.28 58.63 Favored 'Trans proline' 0 C--N 1.302 -1.917 0 C-N-CA 121.609 1.539 . . . . 0.0 110.898 179.494 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.82 -7.77 81.11 Favored Glycine 0 CA--C 1.527 0.841 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -178.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.5 m-85 -112.27 141.72 45.64 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 120.701 0.286 . . . . 0.0 110.377 179.62 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -110.82 133.27 53.5 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.447 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 91.9 t80 -63.83 131.42 47.72 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.862 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -112.87 113.11 50.06 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.048 179.01 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -73.43 -32.06 8.39 Favored 'Trans proline' 0 C--N 1.316 -1.161 0 C-N-CA 121.302 1.334 . . . . 0.0 111.607 -179.739 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.7 t -64.41 -45.89 94.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.412 179.117 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.405 HD12 HG21 ' A' ' 17' ' ' THR . 85.0 mt -81.84 -26.54 34.2 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.262 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.66 3.29 90.57 Favored Glycine 0 CA--C 1.527 0.802 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.617 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.4 pp -134.2 172.98 15.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 120.857 0.361 . . . . 0.0 110.786 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.8 m -88.49 137.68 32.11 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.265 -0.425 . . . . 0.0 109.862 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.405 HG21 HD12 ' A' ' 13' ' ' LEU . 81.3 p -127.65 155.28 44.16 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.978 0.418 . . . . 0.0 110.777 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.8 tt -76.5 144.57 11.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.354 -179.371 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.412 ' OG1' ' O ' ' A' ' 22' ' ' ARG . 9.1 t -146.27 145.0 30.22 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.674 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -140.69 -71.33 0.37 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.455 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 96.3 p -65.42 -23.05 66.85 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.819 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.412 ' O ' ' OG1' ' A' ' 19' ' ' THR . 80.1 ttt180 . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 118.1 -0.952 . . . . 0.0 110.429 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 19.8 mt-30 . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.799 0.333 . . . . 0.0 110.54 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.0 t90 -66.94 128.69 37.29 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.526 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.7 m -121.03 127.07 51.38 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.46 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.681 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.8 OUTLIER -52.3 154.51 4.19 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.567 -179.619 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo -64.49 146.3 89.14 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 121.634 1.556 . . . . 0.0 110.983 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 92.21 -8.26 77.72 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.066 -1.214 . . . . 0.0 110.066 -178.644 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.2 m-85 -108.47 145.77 34.17 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 179.308 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -123.26 134.83 54.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.1 -179.511 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -60.43 131.13 49.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.068 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.64 114.04 47.46 Favored Pre-proline 0 CA--C 1.533 0.299 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.739 179.052 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -72.22 -30.37 13.16 Favored 'Trans proline' 0 C--N 1.315 -1.192 0 C-N-CA 121.363 1.376 . . . . 0.0 111.49 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.5 t -64.04 -45.56 96.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.094 178.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 85.4 mt -84.83 -24.48 28.61 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.293 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.43 0.67 90.08 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.627 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.5 pp -136.23 170.87 17.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.699 0.285 . . . . 0.0 110.618 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 93.9 m -87.57 141.2 28.79 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.908 0.385 . . . . 0.0 110.92 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.9 p -129.06 156.97 43.0 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.111 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.4 tt -71.16 152.5 8.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.254 -179.742 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.497 ' O ' HD22 ' A' ' 20' ' ' LEU . 81.5 p -125.11 152.02 44.93 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.292 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.497 HD22 ' O ' ' A' ' 19' ' ' THR . 0.3 OUTLIER -136.71 -29.83 0.92 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.552 -179.857 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.469 ' CB ' ' O ' ' A' ' 20' ' ' LEU . 1.7 p 79.16 158.36 0.17 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.456 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 9.3 ptm85 . . . . . 0 C--O 1.219 -0.536 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.536 -179.811 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 28.1 mm100 . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.662 0.268 . . . . 0.0 110.532 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.8 t90 -110.79 123.05 49.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.56 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 76.6 m -117.02 126.48 52.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.421 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.668 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.9 OUTLIER -51.2 154.33 2.87 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.471 -179.536 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -64.57 146.57 89.35 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 121.599 1.532 . . . . 0.0 110.944 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 92.17 -8.21 77.84 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.057 -1.217 . . . . 0.0 110.057 -178.661 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 27.4 m-85 -108.99 146.75 33.36 Favored 'General case' 0 C--N 1.332 -0.164 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.296 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -125.01 135.61 52.93 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.031 0.443 . . . . 0.0 111.076 -179.365 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -60.47 131.57 51.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.123 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.86 114.31 46.75 Favored Pre-proline 0 CA--C 1.534 0.36 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.725 179.032 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -71.92 -30.45 13.92 Favored 'Trans proline' 0 C--N 1.315 -1.203 0 C-N-CA 121.329 1.353 . . . . 0.0 111.594 -179.455 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.9 t -64.13 -45.45 96.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.085 178.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.6 mt -85.3 -24.65 27.61 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.389 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.32 0.9 90.23 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.63 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.5 pp -135.82 171.1 17.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.682 0.277 . . . . 0.0 110.464 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 99.1 m -87.94 140.97 28.96 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.875 0.369 . . . . 0.0 110.954 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.2 p -128.89 156.96 42.86 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.932 179.645 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt -68.36 149.93 11.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.382 -179.548 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 80.5 p -129.82 155.17 46.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.09 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 61.8 tp -118.52 123.99 46.46 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.142 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.4 ' O ' ' O ' ' A' ' 22' ' ' ARG . 51.4 m 54.87 39.62 31.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.383 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.4 ' O ' ' O ' ' A' ' 21' ' ' SER . 43.8 ttm180 . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 118.037 -0.983 . . . . 0.0 110.541 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 96.9 mm-40 . . . . . 0 C--O 1.23 0.048 0 CA-C-O 120.721 0.296 . . . . 0.0 110.421 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.8 t90 -118.15 122.83 44.04 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.508 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 74.4 m -117.2 125.87 51.87 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.469 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.679 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.8 OUTLIER -50.2 154.52 2.01 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.467 -179.505 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -64.8 146.29 87.98 Favored 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 121.566 1.511 . . . . 0.0 111.018 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 92.06 -8.16 78.09 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 -178.659 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 26.4 m-85 -108.42 146.12 33.57 Favored 'General case' 0 C--N 1.332 -0.154 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 179.215 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -123.89 135.43 53.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.953 0.406 . . . . 0.0 111.144 -179.481 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.8 t80 -60.45 131.61 51.29 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.041 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -114.03 114.21 46.33 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.769 179.017 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -71.93 -30.5 13.84 Favored 'Trans proline' 0 C--N 1.316 -1.136 0 C-N-CA 121.388 1.392 . . . . 0.0 111.552 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.2 t -64.16 -45.62 95.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.208 179.019 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.42 HD12 HG21 ' A' ' 17' ' ' THR . 84.7 mt -84.86 -24.41 28.58 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.423 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.31 0.86 90.19 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.628 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.5 pp -135.91 171.34 17.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 120.668 0.27 . . . . 0.0 110.557 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 99.1 m -87.98 141.21 28.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.946 0.403 . . . . 0.0 110.792 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.42 HG21 HD12 ' A' ' 13' ' ' LEU . 76.9 p -129.01 157.09 42.67 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.074 179.807 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.2 tt -69.36 151.65 9.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.311 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 80.5 p -128.26 154.73 45.57 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.154 179.856 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 61.6 tp -122.22 123.71 42.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.286 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.5 t -149.29 144.15 26.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.509 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 16.0 mmt180 . . . . . 0 C--O 1.22 -0.5 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.555 179.971 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 5.1 mm100 . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.87 0.366 . . . . 0.0 110.589 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.2 t90 -67.88 129.01 38.6 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.762 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 76.3 m -121.84 129.37 52.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.374 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.664 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 1.0 OUTLIER -53.61 154.37 6.71 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.466 -179.577 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -64.75 146.57 88.7 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 121.617 1.545 . . . . 0.0 110.985 179.46 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 91.8 -7.95 78.79 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 110.154 -1.178 . . . . 0.0 110.154 -178.617 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.6 m-85 -109.51 147.51 32.8 Favored 'General case' 0 C--N 1.333 -0.12 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.266 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -126.17 136.1 52.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.941 0.4 . . . . 0.0 111.126 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 92.8 t80 -60.05 131.34 50.54 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.997 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -115.59 114.17 42.46 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.884 179.088 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -72.26 -30.76 12.6 Favored 'Trans proline' 0 C--N 1.315 -1.189 0 C-N-CA 121.217 1.278 . . . . 0.0 111.452 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.13 -45.22 97.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.361 178.909 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.425 HD12 HG21 ' A' ' 17' ' ' THR . 82.4 mt -85.36 -22.08 28.6 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.442 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.64 -0.5 89.55 Favored Glycine 0 CA--C 1.53 0.999 0 CA-C-N 116.131 -0.486 . . . . 0.0 112.16 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -141.05 176.56 4.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.734 179.703 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 93.0 m -88.05 139.89 30.05 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.02 0.438 . . . . 0.0 111.149 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.425 HG21 HD12 ' A' ' 13' ' ' LEU . 80.5 p -129.15 156.7 43.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.962 179.605 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt -67.76 148.43 11.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.246 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.51 ' O ' HD22 ' A' ' 20' ' ' LEU . 76.6 p -128.82 153.69 47.17 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.312 179.738 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.51 HD22 ' O ' ' A' ' 19' ' ' THR . 0.4 OUTLIER -134.66 -23.07 1.63 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.455 179.944 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.474 ' O ' ' CB ' ' A' ' 22' ' ' ARG . 66.0 m -127.14 149.26 50.04 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.524 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ARG . . . . . 0.474 ' CB ' ' O ' ' A' ' 21' ' ' SER . 5.3 tpp85 . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 117.916 -1.04 . . . . 0.0 110.501 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 71.1 tp60 . . . . . 0 C--O 1.232 0.169 0 CA-C-O 120.642 0.258 . . . . 0.0 110.461 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.2 t90 -107.99 129.53 55.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.711 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 73.5 m -114.96 149.41 37.38 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.327 179.654 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.622 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -72.26 162.69 72.44 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.76 179.407 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -64.96 138.98 59.62 Favored 'Trans proline' 0 C--N 1.302 -1.906 0 C-N-CA 121.734 1.623 . . . . 0.0 110.767 179.43 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.34 -6.9 83.04 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 -178.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 26.2 m-85 -112.73 144.24 42.59 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 179.699 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.92 133.76 55.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.35 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.0 t80 -63.82 130.67 45.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.938 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.04 112.09 50.23 Favored Pre-proline 0 CA--C 1.532 0.273 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.449 179.306 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -74.05 -32.19 7.2 Favored 'Trans proline' 0 C--N 1.317 -1.1 0 C-N-CA 121.397 1.398 . . . . 0.0 111.367 -179.786 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.8 -44.89 96.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.547 179.296 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.539 HD12 HG21 ' A' ' 17' ' ' THR . 76.8 mt -83.38 -22.51 32.74 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.197 -179.657 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.18 2.3 90.47 Favored Glycine 0 CA--C 1.53 0.975 0 CA-C-N 116.151 -0.477 . . . . 0.0 112.617 179.003 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.2 179.72 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-N 117.308 0.554 . . . . 0.0 111.073 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 59.7 m -88.33 137.13 32.6 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.813 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.539 HG21 HD12 ' A' ' 13' ' ' LEU . 82.6 p -128.18 156.75 42.42 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-O 121.038 0.447 . . . . 0.0 110.826 -179.866 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.468 HG12 ' H ' ' A' ' 20' ' ' LEU . 11.0 tt -80.46 142.47 13.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.553 -179.109 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 77.1 p -106.3 8.47 31.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.232 0.539 . . . . 0.0 110.966 -179.647 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.468 ' H ' HG12 ' A' ' 18' ' ' ILE . 61.4 tp -107.32 123.33 48.18 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.166 -0.925 . . . . 0.0 110.457 -179.705 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.3 t -149.98 143.9 25.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.421 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 66.1 ttp85 . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.569 179.923 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 7.5 tp-100 . . . . . 0 C--O 1.23 0.068 0 CA-C-O 120.925 0.393 . . . . 0.0 110.441 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.8 t90 -66.54 133.22 49.91 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.709 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 71.2 m -118.9 150.51 39.76 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.47 179.8 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.624 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -73.49 162.03 76.21 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.718 179.243 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -66.04 138.29 51.72 Favored 'Trans proline' 0 C--N 1.304 -1.812 0 C-N-CA 121.772 1.648 . . . . 0.0 110.77 179.401 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.54 -7.35 82.09 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 -179.02 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 21.3 m-85 -112.04 142.68 44.17 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 179.565 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.41 133.94 54.22 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.558 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.52 130.79 45.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.913 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -114.14 112.99 46.62 Favored Pre-proline 0 CA--C 1.533 0.289 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.272 179.099 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -73.78 -32.79 7.05 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 C-N-CA 121.301 1.334 . . . . 0.0 111.454 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 63.6 t -64.27 -45.66 95.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.497 179.361 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.446 HD12 HG21 ' A' ' 17' ' ' THR . 84.1 mt -81.38 -24.66 36.86 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.395 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.01 1.53 88.72 Favored Glycine 0 CA--C 1.532 1.151 0 CA-C-N 116.189 -0.46 . . . . 0.0 112.595 179.139 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.446 HD13 ' H ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -139.1 179.31 3.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 117.47 0.635 . . . . 0.0 111.043 179.614 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 37.4 m -88.97 135.58 33.47 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 109.878 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.446 HG21 HD12 ' A' ' 13' ' ' LEU . 82.7 p -127.65 154.59 45.09 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-O 121.005 0.431 . . . . 0.0 110.805 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.3 tt -72.03 153.97 7.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.459 -179.35 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 72.3 p -132.2 148.69 52.47 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.772 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 85.0 mt -140.45 145.99 37.67 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.611 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 98.9 p -64.03 -23.47 67.35 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.658 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 78.2 ttt-85 . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 117.968 -1.015 . . . . 0.0 110.58 -179.948 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 25.5 pt20 . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.859 0.361 . . . . 0.0 110.496 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.7 t90 -65.71 134.14 52.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.906 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.1 m -115.93 149.61 38.46 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.252 179.687 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.604 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -75.64 162.31 72.82 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.975 179.504 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -65.68 139.54 58.4 Favored 'Trans proline' 0 C--N 1.303 -1.848 0 C-N-CA 121.77 1.647 . . . . 0.0 110.779 179.213 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.3 -7.55 81.78 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.154 -1.179 . . . . 0.0 110.154 -178.807 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 26.1 m-85 -112.37 143.93 42.66 Favored 'General case' 0 N--CA 1.462 0.157 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.2 134.22 54.68 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.551 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 86.9 t80 -63.4 130.97 46.7 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.891 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -114.56 112.07 46.01 Favored Pre-proline 0 CA--C 1.534 0.344 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.337 179.365 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -73.88 -32.32 7.36 Favored 'Trans proline' 0 C--N 1.316 -1.134 0 C-N-CA 121.338 1.359 . . . . 0.0 111.413 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.5 t -64.71 -45.07 96.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.684 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.59 HD12 HG21 ' A' ' 17' ' ' THR . 76.8 mt -83.06 -22.65 33.44 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.117 -179.573 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.25 2.66 90.37 Favored Glycine 0 CA--C 1.53 0.974 0 CA-C-N 116.168 -0.469 . . . . 0.0 112.51 179.013 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.401 ' C ' HD13 ' A' ' 15' ' ' ILE . 0.0 OUTLIER -138.68 179.54 3.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 117.209 0.505 . . . . 0.0 111.07 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 38.3 m -88.78 134.94 33.77 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.59 HG21 HD12 ' A' ' 13' ' ' LEU . 80.2 p -126.55 154.46 43.83 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 121.012 0.434 . . . . 0.0 110.73 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.2 tt -72.03 155.52 7.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.791 -179.158 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 76.1 p -129.19 157.81 40.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.162 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 1.4 pp -130.11 -16.87 3.54 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.695 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 40.6 t -63.12 139.36 58.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.515 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 66.9 ttp85 . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.496 -179.97 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 4.9 pp0? . . . . . 0 C--O 1.231 0.081 0 CA-C-O 120.759 0.314 . . . . 0.0 110.591 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.6 t90 -138.29 131.62 30.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.869 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.0 m -120.5 149.64 42.1 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.102 0.477 . . . . 0.0 110.544 179.335 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -69.14 158.74 85.75 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.124 179.679 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -55.46 137.69 78.29 Favored 'Trans proline' 0 N--CA 1.499 1.801 0 C-N-CA 121.533 1.488 . . . . 0.0 112.028 179.513 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 87.13 2.36 83.55 Favored Glycine 0 CA--C 1.53 1.018 0 N-CA-C 111.783 -0.527 . . . . 0.0 111.783 179.39 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -120.29 143.61 48.25 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.743 0.306 . . . . 0.0 110.559 179.603 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -111.42 130.1 55.81 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.922 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -63.87 130.96 46.25 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.865 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -112.24 112.99 51.83 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.108 179.214 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -73.35 -31.81 8.79 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.266 1.31 . . . . 0.0 111.487 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.3 t -64.59 -45.89 94.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.363 179.13 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.0 mt -82.25 -27.14 32.63 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.365 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.67 3.69 90.4 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.415 -0.674 . . . . 0.0 111.415 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.601 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.4 pp -133.46 173.03 15.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-O 120.878 0.37 . . . . 0.0 110.923 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 69.0 m -88.33 136.38 33.01 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.065 -179.77 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.2 p -126.39 151.26 47.89 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-O 120.958 0.408 . . . . 0.0 110.628 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.3 tt -72.88 152.29 7.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.563 -179.078 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 59.4 p -131.93 149.3 52.48 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 179.791 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.8 mt -140.04 146.87 39.55 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.575 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 98.7 p -63.42 -23.09 67.25 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.506 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 60.2 ttp180 . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.455 179.992 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.889 0.376 . . . . 0.0 110.609 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.8 t90 -66.45 132.03 47.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.738 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.9 m -118.54 150.24 39.97 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.429 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.627 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -72.55 162.39 74.34 Favored Pre-proline 0 C--N 1.325 -0.464 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.729 179.276 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -65.12 138.94 58.68 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 C-N-CA 121.663 1.576 . . . . 0.0 110.831 179.241 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.1 -6.61 83.46 Favored Glycine 0 CA--C 1.529 0.93 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -178.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -113.28 143.6 44.14 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 179.664 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.25 133.89 54.86 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.423 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 89.2 t80 -63.48 131.03 46.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.045 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -113.98 112.12 47.59 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.404 179.288 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -73.99 -32.13 7.36 Favored 'Trans proline' 0 C--N 1.316 -1.147 0 C-N-CA 121.349 1.366 . . . . 0.0 111.458 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.68 -45.13 96.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.573 179.215 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.556 HD12 HG21 ' A' ' 17' ' ' THR . 77.7 mt -82.63 -22.77 34.6 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.254 -179.726 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.35 2.37 90.28 Favored Glycine 0 CA--C 1.529 0.955 0 CA-C-N 116.086 -0.506 . . . . 0.0 112.574 179.195 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.98 179.43 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.172 0 CA-C-N 117.209 0.504 . . . . 0.0 111.027 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.4 m -88.81 136.3 33.07 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.774 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.556 HG21 HD12 ' A' ' 13' ' ' LEU . 81.9 p -127.66 156.22 42.68 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-O 120.98 0.419 . . . . 0.0 110.816 -179.783 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.463 HG12 ' H ' ' A' ' 20' ' ' LEU . 10.8 tt -78.95 142.86 13.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.495 -179.258 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 75.4 p -105.2 7.88 33.8 Favored 'General case' 0 CA--C 1.519 -0.219 0 CA-C-O 121.285 0.564 . . . . 0.0 111.004 -179.679 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.463 ' H ' HG12 ' A' ' 18' ' ' ILE . 61.3 tp -108.43 123.02 48.21 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.186 -0.916 . . . . 0.0 110.3 -179.824 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 69.0 m -68.79 147.66 51.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.66 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 39.7 ttm105 . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.556 179.827 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 5.5 tm0? . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.784 0.326 . . . . 0.0 110.382 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.0 t90 -139.77 131.4 27.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.774 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 73.0 m -119.18 148.73 42.77 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.367 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.64 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -69.89 159.25 84.85 Favored Pre-proline 0 C--N 1.327 -0.401 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.613 179.072 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -63.18 139.58 73.14 Favored 'Trans proline' 0 C--N 1.302 -1.892 0 C-N-CA 121.631 1.554 . . . . 0.0 111.035 179.642 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 90.3 -6.46 82.44 Favored Glycine 0 CA--C 1.529 0.911 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 -178.885 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 29.9 m-85 -114.79 144.35 43.64 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.666 0.269 . . . . 0.0 110.406 179.754 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.59 133.3 54.7 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.243 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.28 131.16 47.44 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.857 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.89 112.22 47.79 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.504 179.345 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -74.38 -31.74 7.05 Favored 'Trans proline' 0 C--N 1.317 -1.112 0 C-N-CA 121.374 1.383 . . . . 0.0 111.271 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.1 t -64.67 -44.94 96.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.47 179.198 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.532 HD12 HG21 ' A' ' 17' ' ' THR . 76.9 mt -83.8 -22.51 31.78 Favored 'General case' 0 CA--C 1.529 0.154 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.262 -179.572 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.44 2.14 90.19 Favored Glycine 0 CA--C 1.531 1.042 0 CA-C-N 116.199 -0.455 . . . . 0.0 112.573 179.125 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.4 HD13 ' C ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -138.07 -179.11 2.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 117.214 0.507 . . . . 0.0 111.018 179.937 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.7 m -90.8 134.96 34.04 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.177 -0.465 . . . . 0.0 109.84 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.532 HG21 HD12 ' A' ' 13' ' ' LEU . 78.5 p -127.1 153.28 46.2 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-O 120.95 0.405 . . . . 0.0 110.877 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.3 tt -72.22 154.22 7.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.652 -179.16 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 60.0 p -128.73 157.35 41.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.242 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 59.9 tp -135.73 -89.24 0.32 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.365 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 97.5 p -64.6 -23.73 67.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.593 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 40.2 ptt180 . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.657 -179.925 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 64.1 tt0 . . . . . 0 C--O 1.232 0.17 0 CA-C-O 120.794 0.331 . . . . 0.0 110.566 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 92.2 t90 -67.25 132.26 47.39 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.769 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 71.4 m -118.01 149.88 40.21 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.203 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.621 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -72.73 161.98 76.54 Favored Pre-proline 0 C--N 1.325 -0.493 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.75 179.431 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -65.8 138.48 53.51 Favored 'Trans proline' 0 C--N 1.302 -1.901 0 C-N-CA 121.699 1.6 . . . . 0.0 110.846 179.399 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.5 -7.15 82.52 Favored Glycine 0 CA--C 1.527 0.798 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 -178.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -112.12 143.05 43.8 Favored 'General case' 0 C--N 1.332 -0.162 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.63 133.86 54.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.629 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 84.3 t80 -63.2 130.48 44.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.808 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.18 112.22 49.77 Favored Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.347 179.203 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -73.84 -32.11 7.63 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.282 1.322 . . . . 0.0 111.369 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 63.7 t -64.4 -45.07 96.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.505 179.136 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.492 HD12 HG21 ' A' ' 17' ' ' THR . 78.4 mt -83.6 -23.53 31.86 Favored 'General case' 0 CA--C 1.529 0.161 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.294 -179.561 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.09 1.63 89.59 Favored Glycine 0 CA--C 1.53 0.995 0 CA-C-N 116.35 -0.386 . . . . 0.0 112.569 178.992 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.407 HD13 ' H ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -138.15 177.41 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 117.347 0.574 . . . . 0.0 110.975 179.727 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.3 m -87.76 135.27 33.45 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.492 HG21 HD12 ' A' ' 13' ' ' LEU . 81.5 p -127.51 154.47 45.1 Favored 'General case' 0 N--CA 1.462 0.146 0 CA-C-O 120.926 0.393 . . . . 0.0 110.853 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.6 tt -72.02 153.25 7.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.457 -179.397 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 68.2 p -131.55 148.65 52.64 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.0 mt -141.18 145.46 35.7 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.619 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 83.7 p -71.21 160.82 32.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.449 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 83.7 mtt85 . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.979 -1.01 . . . . 0.0 110.608 179.901 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 22.0 mt-30 . . . . . 0 C--O 1.231 0.114 0 CA-C-O 121.07 0.462 . . . . 0.0 110.349 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.0 t90 -69.96 132.6 46.2 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.936 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 77.9 m -116.02 138.05 51.57 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.24 179.698 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.656 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 3.9 pm0 -72.61 158.78 86.8 Favored Pre-proline 0 CA--C 1.535 0.391 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.772 179.833 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_exo -54.32 140.01 73.11 Favored 'Trans proline' 0 N--CA 1.497 1.727 0 C-N-CA 121.23 1.287 . . . . 0.0 111.568 179.194 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 90.81 -8.63 79.52 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.737 -0.945 . . . . 0.0 110.737 -179.71 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 33.1 m-85 -117.16 140.35 49.63 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 110.273 -0.269 . . . . 0.0 110.273 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.99 133.76 54.8 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.349 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 88.2 t80 -62.44 131.47 49.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.921 -179.768 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -114.07 112.26 47.26 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.393 179.028 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -73.61 -31.79 8.36 Favored 'Trans proline' 0 N--CA 1.487 1.103 0 C-N-CA 121.373 1.382 . . . . 0.0 111.404 -179.682 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.0 t -64.93 -44.85 96.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.412 179.333 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.511 HD12 HG21 ' A' ' 17' ' ' THR . 77.0 mt -83.85 -23.64 31.25 Favored 'General case' 0 CA--C 1.53 0.189 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.27 -179.602 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.84 1.62 89.84 Favored Glycine 0 CA--C 1.531 1.077 0 CA-C-N 116.073 -0.512 . . . . 0.0 112.53 179.027 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.16 177.85 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 117.349 0.575 . . . . 0.0 111.056 179.807 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 63.1 m -86.29 137.26 32.74 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.13 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.511 HG21 HD12 ' A' ' 13' ' ' LEU . 76.6 p -128.15 154.37 45.85 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-O 120.797 0.332 . . . . 0.0 110.746 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.5 tt -74.66 151.57 6.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.585 -179.202 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 68.2 p -129.8 155.42 46.0 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.1 179.828 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 60.0 tp -119.45 -38.12 3.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.202 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 93.8 p -153.05 161.83 42.04 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.489 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 78.1 ttt-85 . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.993 -1.004 . . . . 0.0 110.531 -179.945 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 22.0 mp0 . . . . . 0 C--O 1.232 0.162 0 CA-C-O 120.824 0.345 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.7 t90 -67.69 128.95 38.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.716 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 79.8 m -120.73 128.06 52.58 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.393 179.781 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.687 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 1.0 OUTLIER -53.12 154.37 5.53 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.536 -179.46 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo -64.39 146.97 90.63 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 121.574 1.516 . . . . 0.0 111.024 179.597 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 92.06 -7.9 78.3 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 -178.519 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 28.6 m-85 -109.89 146.58 34.9 Favored 'General case' 0 C--O 1.233 0.189 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 179.181 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -124.92 135.39 52.8 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.936 0.398 . . . . 0.0 111.151 -179.469 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -60.29 131.19 50.02 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.113 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.4 114.17 48.02 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.696 178.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -71.82 -30.34 14.36 Favored 'Trans proline' 0 C--N 1.316 -1.164 0 C-N-CA 121.304 1.336 . . . . 0.0 111.525 -179.539 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.3 t -64.2 -45.42 96.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.141 178.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.0 mt -85.43 -24.43 27.47 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.436 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.21 0.89 90.16 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 -179.822 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.629 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.5 pp -135.66 171.16 17.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 120.661 0.267 . . . . 0.0 110.557 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 96.7 m -88.06 141.23 28.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.975 0.417 . . . . 0.0 111.015 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.8 p -128.99 157.05 42.77 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.116 179.465 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt -69.62 147.24 11.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.446 -179.545 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.515 ' C ' HD13 ' A' ' 20' ' ' LEU . 75.4 p -127.38 153.19 46.53 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.306 179.634 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.851 ' N ' HD13 ' A' ' 20' ' ' LEU . 0.0 OUTLIER -141.65 170.72 15.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.141 0.496 . . . . 0.0 111.027 179.983 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 68.2 m -71.9 148.39 46.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.581 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 84.4 mtp180 . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.65 179.903 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 7.3 tp-100 . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.922 0.392 . . . . 0.0 110.4 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 92.0 t90 -67.66 132.58 47.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.79 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.8 m -117.57 150.67 38.6 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.216 179.608 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.61 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -73.89 162.02 75.96 Favored Pre-proline 0 C--N 1.325 -0.473 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.908 179.446 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -65.7 138.68 54.77 Favored 'Trans proline' 0 C--N 1.302 -1.887 0 C-N-CA 121.799 1.666 . . . . 0.0 110.757 179.398 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.62 -7.2 82.35 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 -178.836 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.0 m-85 -112.57 143.35 43.89 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 179.506 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -114.12 133.9 55.25 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.598 -179.737 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 85.6 t80 -62.94 131.02 47.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.917 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -113.96 112.77 47.26 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.262 179.222 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -73.39 -32.52 7.98 Favored 'Trans proline' 0 C--N 1.316 -1.182 0 C-N-CA 121.34 1.36 . . . . 0.0 111.436 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 64.7 t -64.86 -45.29 95.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.653 179.274 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.529 HD12 HG21 ' A' ' 17' ' ' THR . 81.5 mt -81.91 -24.34 35.7 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.363 -179.67 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.21 1.51 89.51 Favored Glycine 0 CA--C 1.531 1.051 0 CA-C-N 116.214 -0.448 . . . . 0.0 112.639 179.122 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.42 HD13 ' H ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -139.06 176.9 5.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 117.366 0.583 . . . . 0.0 111.032 179.67 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 38.8 m -85.78 135.25 33.81 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.529 HG21 HD12 ' A' ' 13' ' ' LEU . 82.6 p -127.95 155.26 44.52 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-O 120.978 0.418 . . . . 0.0 110.845 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.3 tt -74.0 154.45 6.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.582 -179.348 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 58.7 p -128.89 156.56 43.49 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.293 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.765 ' N ' HD23 ' A' ' 20' ' ' LEU . 1.4 pt? -155.78 159.17 39.22 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.7 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 83.2 p -70.97 160.33 33.09 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.497 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 82.4 mtp180 . . . . . 0 C--O 1.219 -0.511 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.529 179.975 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 96.8 mt-30 . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.722 0.296 . . . . 0.0 110.651 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.8 t90 -140.73 134.37 30.2 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.631 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 77.2 m -118.69 149.98 40.52 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.662 179.775 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.609 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -73.92 162.5 73.76 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 115.815 -0.629 . . . . 0.0 109.853 179.263 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -65.1 138.73 57.85 Favored 'Trans proline' 0 C--N 1.302 -1.911 0 C-N-CA 121.637 1.558 . . . . 0.0 110.703 179.343 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.56 -7.35 82.08 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 -178.903 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.9 m-85 -112.97 144.72 42.06 Favored 'General case' 0 N--CA 1.462 0.138 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 179.678 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.93 133.89 55.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.548 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -63.66 130.92 46.27 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.82 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.28 112.27 49.46 Favored Pre-proline 0 CA--C 1.533 0.301 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.403 179.349 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -74.21 -31.99 7.12 Favored 'Trans proline' 0 C--N 1.317 -1.108 0 C-N-CA 121.399 1.399 . . . . 0.0 111.337 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.9 t -64.5 -45.01 96.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.513 179.216 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.491 HD12 HG21 ' A' ' 17' ' ' THR . 74.9 mt -83.66 -22.75 32.05 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.325 -179.351 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.39 2.47 90.22 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-N 116.245 -0.434 . . . . 0.0 112.456 179.115 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.412 HD13 ' C ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -138.23 -179.87 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-N 117.23 0.515 . . . . 0.0 111.07 179.962 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 59.1 m -90.3 135.56 33.6 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.953 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.491 HG21 HD12 ' A' ' 13' ' ' LEU . 82.5 p -127.89 154.46 45.48 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 120.98 0.419 . . . . 0.0 110.792 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.7 tt -72.88 154.61 7.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.568 -179.342 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 70.6 p -128.48 157.53 40.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.364 179.862 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.791 ' N ' HD23 ' A' ' 20' ' ' LEU . 1.5 pt? -152.01 162.36 41.21 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.694 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.0 t -60.92 -44.6 96.98 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.459 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 117.876 -1.059 . . . . 0.0 110.484 179.917 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 4.9 mm100 . . . . . 0 C--O 1.232 0.173 0 CA-C-O 120.724 0.297 . . . . 0.0 110.543 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.1 t90 -67.75 128.98 38.48 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.765 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 82.0 m -121.38 128.4 52.18 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.405 179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.656 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 1.3 pm0 -53.79 154.19 7.38 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.499 -179.504 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -64.5 147.26 90.37 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 121.548 1.499 . . . . 0.0 110.853 179.68 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 92.39 -7.4 77.96 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -178.383 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 32.6 m-85 -112.04 145.98 38.72 Favored 'General case' 0 C--N 1.333 -0.116 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 179.265 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -124.13 135.86 53.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.083 0.468 . . . . 0.0 111.137 -179.257 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 89.8 t80 -60.34 131.51 51.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.196 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.99 114.43 46.34 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.61 178.829 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -71.93 -30.76 13.49 Favored 'Trans proline' 0 C--N 1.315 -1.188 0 C-N-CA 121.255 1.303 . . . . 0.0 111.708 -179.396 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.2 t -64.26 -45.45 96.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.264 178.977 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.414 HD12 HG21 ' A' ' 17' ' ' THR . 84.7 mt -84.54 -24.76 29.16 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.409 -179.818 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.34 0.74 90.09 Favored Glycine 0 CA--C 1.527 0.831 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.638 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.5 pp -135.26 171.68 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.597 0.237 . . . . 0.0 110.463 179.806 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 92.4 m -88.79 140.94 28.93 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.073 0.464 . . . . 0.0 110.976 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.414 HG21 HD12 ' A' ' 13' ' ' LEU . 80.8 p -128.41 155.92 43.98 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.838 179.506 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.4 tt -67.43 143.3 15.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.139 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.7 t -144.86 146.66 32.16 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.606 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.837 ' N ' HD23 ' A' ' 20' ' ' LEU . 0.3 OUTLIER -132.22 36.2 3.64 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.438 -179.702 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 40.8 t -63.49 139.7 58.8 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.432 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 43.5 ttm180 . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.534 -179.977 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 79.1 mt-30 . . . . . 0 C--O 1.232 0.154 0 CA-C-O 120.941 0.4 . . . . 0.0 110.391 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.1 t90 -70.54 133.89 47.19 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.938 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 70.8 m -118.17 148.35 42.45 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.389 179.672 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLN . . . . . 0.662 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -73.56 158.49 86.32 Favored Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.638 179.032 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -61.58 140.32 86.27 Favored 'Trans proline' 0 C--N 1.304 -1.783 0 C-N-CA 121.629 1.553 . . . . 0.0 111.056 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 91.25 -8.39 79.4 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 -178.813 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 46.9 m-85 -113.94 142.07 46.6 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 120.648 0.261 . . . . 0.0 110.426 179.576 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -110.24 132.49 54.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.082 179.474 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -64.03 131.64 48.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.012 -179.637 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -112.73 113.63 50.09 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.122 178.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -73.3 -32.71 7.93 Favored 'Trans proline' 0 C--N 1.316 -1.144 0 C-N-CA 121.257 1.305 . . . . 0.0 111.598 -179.646 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.3 t -64.38 -46.03 94.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.529 179.262 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LEU . . . . . 0.429 HD12 HG21 ' A' ' 17' ' ' THR . 84.6 mt -81.54 -27.07 34.55 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.303 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.73 2.99 90.69 Favored Glycine 0 CA--C 1.528 0.845 0 N-CA-C 111.342 -0.703 . . . . 0.0 111.342 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ILE . . . . . 0.619 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.4 pp -133.03 173.44 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.173 0 CA-C-O 120.865 0.364 . . . . 0.0 110.689 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 48.3 m -87.8 136.89 32.76 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.039 -179.578 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.429 HG21 HD12 ' A' ' 13' ' ' LEU . 82.3 p -128.55 154.23 46.38 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 121.372 0.606 . . . . 0.0 111.287 -179.881 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.74 HD13 ' H ' ' A' ' 19' ' ' THR . 0.4 OUTLIER -72.86 141.79 15.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.223 -0.898 . . . . 0.0 110.462 -179.877 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 19' ' ' THR . . . . . 0.74 ' H ' HD13 ' A' ' 18' ' ' ILE . 11.2 t -144.76 149.46 35.56 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.248 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' LEU . . . . . 0.805 ' N ' HD23 ' A' ' 20' ' ' LEU . 1.5 pt? -151.95 165.12 35.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.941 -179.826 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.1 t -61.09 -43.53 98.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.923 -179.776 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 60.1 ttt85 . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.995 -1.002 . . . . 0.0 110.394 -179.627 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.689 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 35.0 m-85 -118.68 141.27 48.77 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.777 0.322 . . . . 0.0 110.549 179.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.81 133.02 55.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.215 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 91.5 t80 -63.83 131.23 47.14 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.072 -179.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -111.71 112.87 53.36 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.972 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -73.25 -32.08 8.68 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 C-N-CA 121.269 1.313 . . . . 0.0 111.465 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 63.6 t -64.65 -45.62 94.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.47 179.096 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 83.3 mt -82.85 -27.19 30.97 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.392 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.68 3.33 90.55 Favored Glycine 0 CA--C 1.528 0.88 0 N-CA-C 111.367 -0.693 . . . . 0.0 111.367 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.614 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.4 pp -133.18 172.73 15.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 120.812 0.339 . . . . 0.0 110.805 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 83.8 m -87.71 137.92 31.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.203 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.0 p -127.6 153.62 46.2 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.922 0.391 . . . . 0.0 110.504 179.6 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.5 tt . . . . . 0 C--N 1.328 -0.364 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.559 -179.069 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.819 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.5 m-85 -112.64 143.84 43.15 Favored 'General case' 0 C--N 1.333 -0.119 0 N-CA-C 110.217 -0.29 . . . . 0.0 110.217 179.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.3 133.92 54.87 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.607 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 91.7 t80 -64.22 131.72 48.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.854 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -112.37 113.4 51.22 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.073 178.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -73.39 -32.46 8.03 Favored 'Trans proline' 0 N--CA 1.487 1.144 0 C-N-CA 121.294 1.33 . . . . 0.0 111.628 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.0 t -64.57 -45.86 94.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.422 179.305 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.447 HD12 HG21 ' A' ' 17' ' ' THR . 85.3 mt -81.19 -26.61 35.83 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.352 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.58 3.07 90.67 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 111.289 -0.724 . . . . 0.0 111.289 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.617 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.4 pp -134.15 173.18 15.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 120.913 0.387 . . . . 0.0 110.771 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 58.2 m -87.93 136.73 32.83 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.132 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.447 HG21 HD12 ' A' ' 13' ' ' LEU . 82.0 p -127.58 154.85 44.71 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-O 120.978 0.418 . . . . 0.0 110.713 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.4 tt . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.541 -179.355 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.841 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.5 m-85 -112.27 141.72 45.64 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 120.701 0.286 . . . . 0.0 110.377 179.62 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -110.82 133.27 53.5 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.447 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 91.9 t80 -63.83 131.42 47.72 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.862 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -112.87 113.11 50.06 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.048 179.01 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -73.43 -32.06 8.39 Favored 'Trans proline' 0 C--N 1.316 -1.161 0 C-N-CA 121.302 1.334 . . . . 0.0 111.607 -179.739 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.7 t -64.41 -45.89 94.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.412 179.117 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.405 HD12 HG21 ' A' ' 17' ' ' THR . 85.0 mt -81.84 -26.54 34.2 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.262 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.66 3.29 90.57 Favored Glycine 0 CA--C 1.527 0.802 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.617 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.4 pp -134.2 172.98 15.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 120.857 0.361 . . . . 0.0 110.786 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.8 m -88.49 137.68 32.11 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.265 -0.425 . . . . 0.0 109.862 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.405 HG21 HD12 ' A' ' 13' ' ' LEU . 81.3 p -127.65 155.28 44.16 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.978 0.418 . . . . 0.0 110.777 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.8 tt . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.354 -179.371 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.801 0 N-CA-C 110.066 -1.214 . . . . 0.0 110.066 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.2 m-85 -108.47 145.77 34.17 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 179.308 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -123.26 134.83 54.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.1 -179.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -60.43 131.13 49.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.068 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.64 114.04 47.46 Favored Pre-proline 0 CA--C 1.533 0.299 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.739 179.052 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -72.22 -30.37 13.16 Favored 'Trans proline' 0 C--N 1.315 -1.192 0 C-N-CA 121.363 1.376 . . . . 0.0 111.49 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.5 t -64.04 -45.56 96.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.094 178.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 85.4 mt -84.83 -24.48 28.61 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.293 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.43 0.67 90.08 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.627 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.5 pp -136.23 170.87 17.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.699 0.285 . . . . 0.0 110.618 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 93.9 m -87.57 141.2 28.79 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.908 0.385 . . . . 0.0 110.92 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.9 p -129.06 156.97 43.0 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.111 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.4 tt . . . . . 0 C--N 1.327 -0.388 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.254 -179.742 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.716 0 N-CA-C 110.057 -1.217 . . . . 0.0 110.057 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 27.4 m-85 -108.99 146.75 33.36 Favored 'General case' 0 C--N 1.332 -0.164 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.296 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -125.01 135.61 52.93 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.031 0.443 . . . . 0.0 111.076 -179.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -60.47 131.57 51.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.123 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.86 114.31 46.75 Favored Pre-proline 0 CA--C 1.534 0.36 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.725 179.032 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -71.92 -30.45 13.92 Favored 'Trans proline' 0 C--N 1.315 -1.203 0 C-N-CA 121.329 1.353 . . . . 0.0 111.594 -179.455 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.9 t -64.13 -45.45 96.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.085 178.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.6 mt -85.3 -24.65 27.61 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.389 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.32 0.9 90.23 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.63 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.5 pp -135.82 171.1 17.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.682 0.277 . . . . 0.0 110.464 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 99.1 m -87.94 140.97 28.96 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.875 0.369 . . . . 0.0 110.954 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.2 p -128.89 156.96 42.86 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.932 179.645 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt . . . . . 0 C--N 1.328 -0.358 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.382 -179.548 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.768 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 26.4 m-85 -108.42 146.12 33.57 Favored 'General case' 0 C--N 1.332 -0.154 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 179.215 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -123.89 135.43 53.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.953 0.406 . . . . 0.0 111.144 -179.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.8 t80 -60.45 131.61 51.29 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.041 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -114.03 114.21 46.33 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.769 179.017 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -71.93 -30.5 13.84 Favored 'Trans proline' 0 C--N 1.316 -1.136 0 C-N-CA 121.388 1.392 . . . . 0.0 111.552 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.2 t -64.16 -45.62 95.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.208 179.019 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.42 HD12 HG21 ' A' ' 17' ' ' THR . 84.7 mt -84.86 -24.41 28.58 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.423 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.31 0.86 90.19 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.628 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.5 pp -135.91 171.34 17.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 120.668 0.27 . . . . 0.0 110.557 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 99.1 m -87.98 141.21 28.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.946 0.403 . . . . 0.0 110.792 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.42 HG21 HD12 ' A' ' 13' ' ' LEU . 76.9 p -129.01 157.09 42.67 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.074 179.807 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.2 tt . . . . . 0 C--N 1.327 -0.371 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.311 -179.632 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.777 0 N-CA-C 110.154 -1.178 . . . . 0.0 110.154 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.6 m-85 -109.51 147.51 32.8 Favored 'General case' 0 C--N 1.333 -0.12 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.266 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -126.17 136.1 52.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.941 0.4 . . . . 0.0 111.126 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 92.8 t80 -60.05 131.34 50.54 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.997 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -115.59 114.17 42.46 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.884 179.088 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -72.26 -30.76 12.6 Favored 'Trans proline' 0 C--N 1.315 -1.189 0 C-N-CA 121.217 1.278 . . . . 0.0 111.452 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.13 -45.22 97.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.361 178.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.425 HD12 HG21 ' A' ' 17' ' ' THR . 82.4 mt -85.36 -22.08 28.6 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.442 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.64 -0.5 89.55 Favored Glycine 0 CA--C 1.53 0.999 0 CA-C-N 116.131 -0.486 . . . . 0.0 112.16 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -141.05 176.56 4.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.734 179.703 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 93.0 m -88.05 139.89 30.05 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.02 0.438 . . . . 0.0 111.149 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.425 HG21 HD12 ' A' ' 13' ' ' LEU . 80.5 p -129.15 156.7 43.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.962 179.605 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt . . . . . 0 C--N 1.327 -0.411 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.246 -179.658 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.825 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 26.2 m-85 -112.73 144.24 42.59 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 179.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.92 133.76 55.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.35 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.0 t80 -63.82 130.67 45.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.938 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.04 112.09 50.23 Favored Pre-proline 0 CA--C 1.532 0.273 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.449 179.306 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -74.05 -32.19 7.2 Favored 'Trans proline' 0 C--N 1.317 -1.1 0 C-N-CA 121.397 1.398 . . . . 0.0 111.367 -179.786 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.8 -44.89 96.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.547 179.296 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.539 HD12 HG21 ' A' ' 17' ' ' THR . 76.8 mt -83.38 -22.51 32.74 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.197 -179.657 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.18 2.3 90.47 Favored Glycine 0 CA--C 1.53 0.975 0 CA-C-N 116.151 -0.477 . . . . 0.0 112.617 179.003 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.2 179.72 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-N 117.308 0.554 . . . . 0.0 111.073 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 59.7 m -88.33 137.13 32.6 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.813 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.539 HG21 HD12 ' A' ' 13' ' ' LEU . 82.6 p -128.18 156.75 42.42 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-O 121.038 0.447 . . . . 0.0 110.826 -179.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.0 tt . . . . . 0 C--N 1.33 -0.241 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.553 -179.109 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.814 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 21.3 m-85 -112.04 142.68 44.17 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 179.565 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.41 133.94 54.22 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.558 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.52 130.79 45.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.913 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -114.14 112.99 46.62 Favored Pre-proline 0 CA--C 1.533 0.289 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.272 179.099 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -73.78 -32.79 7.05 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 C-N-CA 121.301 1.334 . . . . 0.0 111.454 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 63.6 t -64.27 -45.66 95.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.497 179.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.446 HD12 HG21 ' A' ' 17' ' ' THR . 84.1 mt -81.38 -24.66 36.86 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.395 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.01 1.53 88.72 Favored Glycine 0 CA--C 1.532 1.151 0 CA-C-N 116.189 -0.46 . . . . 0.0 112.595 179.139 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.446 HD13 ' H ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -139.1 179.31 3.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 117.47 0.635 . . . . 0.0 111.043 179.614 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 37.4 m -88.97 135.58 33.47 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 109.878 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.446 HG21 HD12 ' A' ' 13' ' ' LEU . 82.7 p -127.65 154.59 45.09 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-O 121.005 0.431 . . . . 0.0 110.805 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.3 tt . . . . . 0 C--N 1.33 -0.239 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.459 -179.35 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.525 0.711 0 N-CA-C 110.154 -1.179 . . . . 0.0 110.154 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 26.1 m-85 -112.37 143.93 42.66 Favored 'General case' 0 N--CA 1.462 0.157 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.2 134.22 54.68 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.551 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 86.9 t80 -63.4 130.97 46.7 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.891 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -114.56 112.07 46.01 Favored Pre-proline 0 CA--C 1.534 0.344 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.337 179.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -73.88 -32.32 7.36 Favored 'Trans proline' 0 C--N 1.316 -1.134 0 C-N-CA 121.338 1.359 . . . . 0.0 111.413 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.5 t -64.71 -45.07 96.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.684 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.59 HD12 HG21 ' A' ' 17' ' ' THR . 76.8 mt -83.06 -22.65 33.44 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.117 -179.573 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.25 2.66 90.37 Favored Glycine 0 CA--C 1.53 0.974 0 CA-C-N 116.168 -0.469 . . . . 0.0 112.51 179.013 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.401 ' C ' HD13 ' A' ' 15' ' ' ILE . 0.0 OUTLIER -138.68 179.54 3.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 117.209 0.505 . . . . 0.0 111.07 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 38.3 m -88.78 134.94 33.77 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.59 HG21 HD12 ' A' ' 13' ' ' LEU . 80.2 p -126.55 154.46 43.83 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 121.012 0.434 . . . . 0.0 110.73 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.2 tt . . . . . 0 C--N 1.328 -0.363 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.791 -179.158 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.53 1.018 0 N-CA-C 111.783 -0.527 . . . . 0.0 111.783 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 38.6 m-85 -120.29 143.61 48.25 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.743 0.306 . . . . 0.0 110.559 179.603 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -111.42 130.1 55.81 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.922 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -63.87 130.96 46.25 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.865 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -112.24 112.99 51.83 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.108 179.214 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -73.35 -31.81 8.79 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.266 1.31 . . . . 0.0 111.487 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.3 t -64.59 -45.89 94.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.363 179.13 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.0 mt -82.25 -27.14 32.63 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.365 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.67 3.69 90.4 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.415 -0.674 . . . . 0.0 111.415 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.601 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.4 pp -133.46 173.03 15.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-O 120.878 0.37 . . . . 0.0 110.923 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 69.0 m -88.33 136.38 33.01 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.065 -179.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.2 p -126.39 151.26 47.89 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-O 120.958 0.408 . . . . 0.0 110.628 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.3 tt . . . . . 0 C--N 1.327 -0.388 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.563 -179.078 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.93 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -113.28 143.6 44.14 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 179.664 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.25 133.89 54.86 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.423 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 89.2 t80 -63.48 131.03 46.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.045 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -113.98 112.12 47.59 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.404 179.288 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -73.99 -32.13 7.36 Favored 'Trans proline' 0 C--N 1.316 -1.147 0 C-N-CA 121.349 1.366 . . . . 0.0 111.458 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.68 -45.13 96.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.573 179.215 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.556 HD12 HG21 ' A' ' 17' ' ' THR . 77.7 mt -82.63 -22.77 34.6 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.254 -179.726 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.35 2.37 90.28 Favored Glycine 0 CA--C 1.529 0.955 0 CA-C-N 116.086 -0.506 . . . . 0.0 112.574 179.195 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.98 179.43 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.172 0 CA-C-N 117.209 0.504 . . . . 0.0 111.027 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.4 m -88.81 136.3 33.07 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.774 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.556 HG21 HD12 ' A' ' 13' ' ' LEU . 81.9 p -127.66 156.22 42.68 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-O 120.98 0.419 . . . . 0.0 110.816 -179.783 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.8 tt . . . . . 0 C--N 1.329 -0.284 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.495 -179.258 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.529 0.911 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 29.9 m-85 -114.79 144.35 43.64 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.666 0.269 . . . . 0.0 110.406 179.754 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.59 133.3 54.7 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.243 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.28 131.16 47.44 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.857 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.89 112.22 47.79 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.504 179.345 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -74.38 -31.74 7.05 Favored 'Trans proline' 0 C--N 1.317 -1.112 0 C-N-CA 121.374 1.383 . . . . 0.0 111.271 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.1 t -64.67 -44.94 96.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.47 179.198 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.532 HD12 HG21 ' A' ' 17' ' ' THR . 76.9 mt -83.8 -22.51 31.78 Favored 'General case' 0 CA--C 1.529 0.154 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.262 -179.572 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.44 2.14 90.19 Favored Glycine 0 CA--C 1.531 1.042 0 CA-C-N 116.199 -0.455 . . . . 0.0 112.573 179.125 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.4 HD13 ' C ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -138.07 -179.11 2.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 117.214 0.507 . . . . 0.0 111.018 179.937 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.7 m -90.8 134.96 34.04 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.177 -0.465 . . . . 0.0 109.84 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.532 HG21 HD12 ' A' ' 13' ' ' LEU . 78.5 p -127.1 153.28 46.2 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-O 120.95 0.405 . . . . 0.0 110.877 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.3 tt . . . . . 0 C--N 1.328 -0.351 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.652 -179.16 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.798 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -112.12 143.05 43.8 Favored 'General case' 0 C--N 1.332 -0.162 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.63 133.86 54.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.629 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 84.3 t80 -63.2 130.48 44.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.808 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.18 112.22 49.77 Favored Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.347 179.203 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -73.84 -32.11 7.63 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.282 1.322 . . . . 0.0 111.369 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 63.7 t -64.4 -45.07 96.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.505 179.136 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.492 HD12 HG21 ' A' ' 17' ' ' THR . 78.4 mt -83.6 -23.53 31.86 Favored 'General case' 0 CA--C 1.529 0.161 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.294 -179.561 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.09 1.63 89.59 Favored Glycine 0 CA--C 1.53 0.995 0 CA-C-N 116.35 -0.386 . . . . 0.0 112.569 178.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.407 HD13 ' H ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -138.15 177.41 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 117.347 0.574 . . . . 0.0 110.975 179.727 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.3 m -87.76 135.27 33.45 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.492 HG21 HD12 ' A' ' 13' ' ' LEU . 81.5 p -127.51 154.47 45.1 Favored 'General case' 0 N--CA 1.462 0.146 0 CA-C-O 120.926 0.393 . . . . 0.0 110.853 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.6 tt . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.457 -179.397 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.724 0 N-CA-C 110.737 -0.945 . . . . 0.0 110.737 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 33.1 m-85 -117.16 140.35 49.63 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 110.273 -0.269 . . . . 0.0 110.273 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.99 133.76 54.8 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.349 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 88.2 t80 -62.44 131.47 49.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.921 -179.768 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -114.07 112.26 47.26 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.393 179.028 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -73.61 -31.79 8.36 Favored 'Trans proline' 0 N--CA 1.487 1.103 0 C-N-CA 121.373 1.382 . . . . 0.0 111.404 -179.682 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.0 t -64.93 -44.85 96.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.412 179.333 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.511 HD12 HG21 ' A' ' 17' ' ' THR . 77.0 mt -83.85 -23.64 31.25 Favored 'General case' 0 CA--C 1.53 0.189 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.27 -179.602 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.84 1.62 89.84 Favored Glycine 0 CA--C 1.531 1.077 0 CA-C-N 116.073 -0.512 . . . . 0.0 112.53 179.027 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.16 177.85 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 117.349 0.575 . . . . 0.0 111.056 179.807 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 63.1 m -86.29 137.26 32.74 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.13 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.511 HG21 HD12 ' A' ' 13' ' ' LEU . 76.6 p -128.15 154.37 45.85 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-O 120.797 0.332 . . . . 0.0 110.746 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.5 tt . . . . . 0 C--N 1.327 -0.384 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.585 -179.202 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.788 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 28.6 m-85 -109.89 146.58 34.9 Favored 'General case' 0 C--O 1.233 0.189 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 179.181 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -124.92 135.39 52.8 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.936 0.398 . . . . 0.0 111.151 -179.469 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -60.29 131.19 50.02 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.113 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.4 114.17 48.02 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.696 178.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -71.82 -30.34 14.36 Favored 'Trans proline' 0 C--N 1.316 -1.164 0 C-N-CA 121.304 1.336 . . . . 0.0 111.525 -179.539 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.3 t -64.2 -45.42 96.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.141 178.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.0 mt -85.43 -24.43 27.47 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.436 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.21 0.89 90.16 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 -179.822 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.629 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.5 pp -135.66 171.16 17.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 120.661 0.267 . . . . 0.0 110.557 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 96.7 m -88.06 141.23 28.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.975 0.417 . . . . 0.0 111.015 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.8 p -128.99 157.05 42.77 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.116 179.465 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt . . . . . 0 C--N 1.326 -0.432 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.446 -179.545 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.836 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.0 m-85 -112.57 143.35 43.89 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 179.506 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -114.12 133.9 55.25 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.598 -179.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 85.6 t80 -62.94 131.02 47.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.917 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -113.96 112.77 47.26 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.262 179.222 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -73.39 -32.52 7.98 Favored 'Trans proline' 0 C--N 1.316 -1.182 0 C-N-CA 121.34 1.36 . . . . 0.0 111.436 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 64.7 t -64.86 -45.29 95.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.653 179.274 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.529 HD12 HG21 ' A' ' 17' ' ' THR . 81.5 mt -81.91 -24.34 35.7 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.363 -179.67 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.21 1.51 89.51 Favored Glycine 0 CA--C 1.531 1.051 0 CA-C-N 116.214 -0.448 . . . . 0.0 112.639 179.122 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.42 HD13 ' H ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -139.06 176.9 5.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 117.366 0.583 . . . . 0.0 111.032 179.67 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 38.8 m -85.78 135.25 33.81 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.529 HG21 HD12 ' A' ' 13' ' ' LEU . 82.6 p -127.95 155.26 44.52 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-O 120.978 0.418 . . . . 0.0 110.845 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.3 tt . . . . . 0 C--N 1.331 -0.226 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.582 -179.348 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.825 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.9 m-85 -112.97 144.72 42.06 Favored 'General case' 0 N--CA 1.462 0.138 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 179.678 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.93 133.89 55.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.548 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -63.66 130.92 46.27 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.82 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.28 112.27 49.46 Favored Pre-proline 0 CA--C 1.533 0.301 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.403 179.349 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -74.21 -31.99 7.12 Favored 'Trans proline' 0 C--N 1.317 -1.108 0 C-N-CA 121.399 1.399 . . . . 0.0 111.337 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.9 t -64.5 -45.01 96.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.513 179.216 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.491 HD12 HG21 ' A' ' 17' ' ' THR . 74.9 mt -83.66 -22.75 32.05 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.325 -179.351 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.39 2.47 90.22 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-N 116.245 -0.434 . . . . 0.0 112.456 179.115 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.412 HD13 ' C ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -138.23 -179.87 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-N 117.23 0.515 . . . . 0.0 111.07 179.962 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 59.1 m -90.3 135.56 33.6 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.953 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.491 HG21 HD12 ' A' ' 13' ' ' LEU . 82.5 p -127.89 154.46 45.48 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 120.98 0.419 . . . . 0.0 110.792 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.7 tt . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.568 -179.342 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.526 0.735 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 32.6 m-85 -112.04 145.98 38.72 Favored 'General case' 0 C--N 1.333 -0.116 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 179.265 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -124.13 135.86 53.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.083 0.468 . . . . 0.0 111.137 -179.257 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 89.8 t80 -60.34 131.51 51.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.196 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.99 114.43 46.34 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.61 178.829 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -71.93 -30.76 13.49 Favored 'Trans proline' 0 C--N 1.315 -1.188 0 C-N-CA 121.255 1.303 . . . . 0.0 111.708 -179.396 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.2 t -64.26 -45.45 96.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.264 178.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.414 HD12 HG21 ' A' ' 17' ' ' THR . 84.7 mt -84.54 -24.76 29.16 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.409 -179.818 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.34 0.74 90.09 Favored Glycine 0 CA--C 1.527 0.831 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.638 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.5 pp -135.26 171.68 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.597 0.237 . . . . 0.0 110.463 179.806 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 92.4 m -88.79 140.94 28.93 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.073 0.464 . . . . 0.0 110.976 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.414 HG21 HD12 ' A' ' 13' ' ' LEU . 80.8 p -128.41 155.92 43.98 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.838 179.506 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.4 tt . . . . . 0 C--N 1.327 -0.395 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.139 -179.421 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.79 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 46.9 m-85 -113.94 142.07 46.6 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 120.648 0.261 . . . . 0.0 110.426 179.576 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -110.24 132.49 54.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.082 179.474 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -64.03 131.64 48.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.012 -179.637 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -112.73 113.63 50.09 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.122 178.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -73.3 -32.71 7.93 Favored 'Trans proline' 0 C--N 1.316 -1.144 0 C-N-CA 121.257 1.305 . . . . 0.0 111.598 -179.646 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.3 t -64.38 -46.03 94.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.529 179.262 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' LEU . . . . . 0.429 HD12 HG21 ' A' ' 17' ' ' THR . 84.6 mt -81.54 -27.07 34.55 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.303 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.73 2.99 90.69 Favored Glycine 0 CA--C 1.528 0.845 0 N-CA-C 111.342 -0.703 . . . . 0.0 111.342 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ILE . . . . . 0.619 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.4 pp -133.03 173.44 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.173 0 CA-C-O 120.865 0.364 . . . . 0.0 110.689 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 48.3 m -87.8 136.89 32.76 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.039 -179.578 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.429 HG21 HD12 ' A' ' 13' ' ' LEU . 82.3 p -128.55 154.23 46.38 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 121.372 0.606 . . . . 0.0 111.287 -179.881 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.325 -0.459 0 CA-C-N 115.223 -0.898 . . . . 0.0 110.462 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 18.1 mt-30 . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.82 0.343 . . . . 0.0 110.494 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.7 t90 -135.17 129.15 33.35 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.366 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 64.7 m -111.26 133.75 53.36 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.545 -179.739 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.668 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 6.5 pm0 -71.64 159.0 86.76 Favored Pre-proline 0 CA--C 1.536 0.441 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.34 179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_exo -52.28 140.12 52.82 Favored 'Trans proline' 0 N--CA 1.498 1.751 0 C-N-CA 121.263 1.309 . . . . 0.0 111.833 179.739 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 91.75 -7.87 78.99 Favored Glycine 0 CA--C 1.525 0.689 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 -179.569 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.507 ' CG ' ' NE2' ' A' ' 4' ' ' GLN . 35.0 m-85 -118.68 141.27 48.77 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.777 0.322 . . . . 0.0 110.549 179.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.81 133.02 55.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.215 179.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 91.5 t80 -63.83 131.23 47.14 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.072 -179.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -111.71 112.87 53.36 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.972 179.014 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -73.25 -32.08 8.68 Favored 'Trans proline' 0 C--N 1.315 -1.229 0 C-N-CA 121.269 1.313 . . . . 0.0 111.465 -179.69 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 63.6 t -64.65 -45.62 94.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.47 179.096 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 83.3 mt -82.85 -27.19 30.97 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.392 -179.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.68 3.33 90.55 Favored Glycine 0 CA--C 1.528 0.88 0 N-CA-C 111.367 -0.693 . . . . 0.0 111.367 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.614 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.4 pp -133.18 172.73 15.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 120.812 0.339 . . . . 0.0 110.805 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 83.8 m -87.71 137.92 31.92 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.203 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.0 p -127.6 153.62 46.2 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-O 120.922 0.391 . . . . 0.0 110.504 179.6 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.5 tt -72.72 149.91 8.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.559 -179.069 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.6 t -149.63 148.56 29.46 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.129 179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -120.29 -13.44 8.89 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.411 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 51.0 m 53.59 39.96 30.79 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.811 179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 61.2 ttp180 . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.125 -0.94 . . . . 0.0 110.511 179.874 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . 0.425 ' OE1' ' N ' ' A' ' 1' ' ' GLN . 13.1 pm0 . . . . . 0 N--CA 1.457 -0.108 0 CA-C-O 120.817 0.341 . . . . 0.0 110.703 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.5 t90 -138.62 132.9 31.7 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.533 -179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 74.2 m -118.85 150.37 39.96 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.563 179.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.693 ' NE2' ' H ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -72.97 162.34 75.01 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.712 179.23 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_endo -65.14 138.9 58.38 Favored 'Trans proline' 0 C--N 1.302 -1.916 0 C-N-CA 121.698 1.599 . . . . 0.0 110.765 179.333 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.43 -7.81 81.18 Favored Glycine 0 CA--C 1.527 0.819 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 -178.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.5 m-85 -112.64 143.84 43.15 Favored 'General case' 0 C--N 1.333 -0.119 0 N-CA-C 110.217 -0.29 . . . . 0.0 110.217 179.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.3 133.92 54.87 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.607 -179.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 91.7 t80 -64.22 131.72 48.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.854 -179.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -112.37 113.4 51.22 Favored Pre-proline 0 C--N 1.33 -0.274 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.073 178.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -73.39 -32.46 8.03 Favored 'Trans proline' 0 N--CA 1.487 1.144 0 C-N-CA 121.294 1.33 . . . . 0.0 111.628 -179.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.0 t -64.57 -45.86 94.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.422 179.305 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.447 HD12 HG21 ' A' ' 17' ' ' THR . 85.3 mt -81.19 -26.61 35.83 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.352 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.58 3.07 90.67 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 111.289 -0.724 . . . . 0.0 111.289 -179.883 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.617 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.4 pp -134.15 173.18 15.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.198 0 CA-C-O 120.913 0.387 . . . . 0.0 110.771 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 58.2 m -87.93 136.73 32.83 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.132 -179.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.447 HG21 HD12 ' A' ' 13' ' ' LEU . 82.0 p -127.58 154.85 44.71 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-O 120.978 0.418 . . . . 0.0 110.713 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.4 tt -72.98 149.08 8.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.541 -179.355 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 10.3 t -151.13 143.76 24.36 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 95.0 mt -129.95 144.23 51.22 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.642 -179.702 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.0 t -61.1 -44.33 97.52 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.955 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 118.024 -0.988 . . . . 0.0 110.608 -179.786 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 22.9 mm100 . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.87 0.367 . . . . 0.0 110.613 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.6 t90 -66.03 132.94 49.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.793 179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.6 m -118.58 150.41 39.72 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.435 179.739 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.698 ' NE2' ' H ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -72.87 162.15 75.84 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.702 179.334 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -64.57 138.28 58.63 Favored 'Trans proline' 0 C--N 1.302 -1.917 0 C-N-CA 121.609 1.539 . . . . 0.0 110.898 179.494 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.82 -7.77 81.11 Favored Glycine 0 CA--C 1.527 0.841 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 -178.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.5 m-85 -112.27 141.72 45.64 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-O 120.701 0.286 . . . . 0.0 110.377 179.62 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -110.82 133.27 53.5 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.447 -179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 91.9 t80 -63.83 131.42 47.72 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.862 179.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -112.87 113.11 50.06 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.048 179.01 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -73.43 -32.06 8.39 Favored 'Trans proline' 0 C--N 1.316 -1.161 0 C-N-CA 121.302 1.334 . . . . 0.0 111.607 -179.739 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.7 t -64.41 -45.89 94.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.412 179.117 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.405 HD12 HG21 ' A' ' 17' ' ' THR . 85.0 mt -81.84 -26.54 34.2 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.262 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.66 3.29 90.57 Favored Glycine 0 CA--C 1.527 0.802 0 N-CA-C 111.31 -0.716 . . . . 0.0 111.31 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.617 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.4 pp -134.2 172.98 15.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-O 120.857 0.361 . . . . 0.0 110.786 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.8 m -88.49 137.68 32.11 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.265 -0.425 . . . . 0.0 109.862 -179.736 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.405 HG21 HD12 ' A' ' 13' ' ' LEU . 81.3 p -127.65 155.28 44.16 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.978 0.418 . . . . 0.0 110.777 179.961 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.8 tt -76.5 144.57 11.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.354 -179.371 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.412 ' OG1' ' O ' ' A' ' 22' ' ' ARG . 9.1 t -146.27 145.0 30.22 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.674 179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -140.69 -71.33 0.37 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.455 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 96.3 p -65.42 -23.05 66.85 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.819 -179.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.412 ' O ' ' OG1' ' A' ' 19' ' ' THR . 80.1 ttt180 . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 118.1 -0.952 . . . . 0.0 110.429 -179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 19.8 mt-30 . . . . . 0 C--O 1.231 0.091 0 CA-C-O 120.799 0.333 . . . . 0.0 110.54 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.0 t90 -66.94 128.69 37.29 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.526 -179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.7 m -121.03 127.07 51.38 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.46 179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.681 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.8 OUTLIER -52.3 154.51 4.19 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.567 -179.619 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo -64.49 146.3 89.14 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 C-N-CA 121.634 1.556 . . . . 0.0 110.983 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 92.21 -8.26 77.72 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.066 -1.214 . . . . 0.0 110.066 -178.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.2 m-85 -108.47 145.77 34.17 Favored 'General case' 0 C--N 1.332 -0.184 0 N-CA-C 109.569 -0.53 . . . . 0.0 109.569 179.308 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -123.26 134.83 54.06 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.1 -179.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.7 t80 -60.43 131.13 49.81 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.885 -0.598 . . . . 0.0 111.068 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.64 114.04 47.46 Favored Pre-proline 0 CA--C 1.533 0.299 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.739 179.052 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -72.22 -30.37 13.16 Favored 'Trans proline' 0 C--N 1.315 -1.192 0 C-N-CA 121.363 1.376 . . . . 0.0 111.49 -179.555 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.5 t -64.04 -45.56 96.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.094 178.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 85.4 mt -84.83 -24.48 28.61 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.293 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.43 0.67 90.08 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.627 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.5 pp -136.23 170.87 17.86 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-O 120.699 0.285 . . . . 0.0 110.618 179.881 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 93.9 m -87.57 141.2 28.79 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.908 0.385 . . . . 0.0 110.92 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 76.9 p -129.06 156.97 43.0 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.111 179.666 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 14.4 tt -71.16 152.5 8.59 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.254 -179.742 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.497 ' O ' HD22 ' A' ' 20' ' ' LEU . 81.5 p -125.11 152.02 44.93 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.292 179.902 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.497 HD22 ' O ' ' A' ' 19' ' ' THR . 0.3 OUTLIER -136.71 -29.83 0.92 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.552 -179.857 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.469 ' CB ' ' O ' ' A' ' 20' ' ' LEU . 1.7 p 79.16 158.36 0.17 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.456 -179.817 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 9.3 ptm85 . . . . . 0 C--O 1.219 -0.536 0 CA-C-O 118.023 -0.989 . . . . 0.0 110.536 -179.811 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 28.1 mm100 . . . . . 0 C--O 1.232 0.146 0 CA-C-O 120.662 0.268 . . . . 0.0 110.532 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.8 t90 -110.79 123.05 49.33 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.56 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 76.6 m -117.02 126.48 52.95 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.421 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.668 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.9 OUTLIER -51.2 154.33 2.87 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.471 -179.536 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -64.57 146.57 89.35 Favored 'Trans proline' 0 C--N 1.309 -1.518 0 C-N-CA 121.599 1.532 . . . . 0.0 110.944 179.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 92.17 -8.21 77.84 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.057 -1.217 . . . . 0.0 110.057 -178.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 27.4 m-85 -108.99 146.75 33.36 Favored 'General case' 0 C--N 1.332 -0.164 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.296 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -125.01 135.61 52.93 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.031 0.443 . . . . 0.0 111.076 -179.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -60.47 131.57 51.17 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.123 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.86 114.31 46.75 Favored Pre-proline 0 CA--C 1.534 0.36 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.725 179.032 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -71.92 -30.45 13.92 Favored 'Trans proline' 0 C--N 1.315 -1.203 0 C-N-CA 121.329 1.353 . . . . 0.0 111.594 -179.455 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.9 t -64.13 -45.45 96.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.085 178.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.6 mt -85.3 -24.65 27.61 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.389 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.32 0.9 90.23 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.63 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.5 pp -135.82 171.1 17.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.682 0.277 . . . . 0.0 110.464 179.958 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 99.1 m -87.94 140.97 28.96 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.875 0.369 . . . . 0.0 110.954 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.2 p -128.89 156.96 42.86 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.932 179.645 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt -68.36 149.93 11.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.382 -179.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 80.5 p -129.82 155.17 46.41 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.09 179.736 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 61.8 tp -118.52 123.99 46.46 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.142 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.4 ' O ' ' O ' ' A' ' 22' ' ' ARG . 51.4 m 54.87 39.62 31.58 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.383 -179.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.4 ' O ' ' O ' ' A' ' 21' ' ' SER . 43.8 ttm180 . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 118.037 -0.983 . . . . 0.0 110.541 -179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 96.9 mm-40 . . . . . 0 C--O 1.23 0.048 0 CA-C-O 120.721 0.296 . . . . 0.0 110.421 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.8 t90 -118.15 122.83 44.04 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.508 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 74.4 m -117.2 125.87 51.87 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.469 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.679 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.8 OUTLIER -50.2 154.52 2.01 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.467 -179.505 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -64.8 146.29 87.98 Favored 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 121.566 1.511 . . . . 0.0 111.018 179.465 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 92.06 -8.16 78.09 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 110.117 -1.193 . . . . 0.0 110.117 -178.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 26.4 m-85 -108.42 146.12 33.57 Favored 'General case' 0 C--N 1.332 -0.154 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 179.215 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -123.89 135.43 53.71 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.953 0.406 . . . . 0.0 111.144 -179.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.8 t80 -60.45 131.61 51.29 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.041 179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -114.03 114.21 46.33 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.769 179.017 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -71.93 -30.5 13.84 Favored 'Trans proline' 0 C--N 1.316 -1.136 0 C-N-CA 121.388 1.392 . . . . 0.0 111.552 -179.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.2 t -64.16 -45.62 95.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.208 179.019 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.42 HD12 HG21 ' A' ' 17' ' ' THR . 84.7 mt -84.86 -24.41 28.58 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.423 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.31 0.86 90.19 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 -179.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.628 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.5 pp -135.91 171.34 17.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 120.668 0.27 . . . . 0.0 110.557 179.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 99.1 m -87.98 141.21 28.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.946 0.403 . . . . 0.0 110.792 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.42 HG21 HD12 ' A' ' 13' ' ' LEU . 76.9 p -129.01 157.09 42.67 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.074 179.807 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.2 tt -69.36 151.65 9.81 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.311 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 80.5 p -128.26 154.73 45.57 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.154 179.856 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 61.6 tp -122.22 123.71 42.12 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.286 -179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.5 t -149.29 144.15 26.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.509 179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 16.0 mmt180 . . . . . 0 C--O 1.22 -0.5 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.555 179.971 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 5.1 mm100 . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.87 0.366 . . . . 0.0 110.589 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.2 t90 -67.88 129.01 38.6 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.762 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 76.3 m -121.84 129.37 52.56 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.374 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.664 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 1.0 OUTLIER -53.61 154.37 6.71 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.466 -179.577 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -64.75 146.57 88.7 Favored 'Trans proline' 0 C--N 1.309 -1.529 0 C-N-CA 121.617 1.545 . . . . 0.0 110.985 179.46 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 91.8 -7.95 78.79 Favored Glycine 0 CA--C 1.526 0.777 0 N-CA-C 110.154 -1.178 . . . . 0.0 110.154 -178.617 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.6 m-85 -109.51 147.51 32.8 Favored 'General case' 0 C--N 1.333 -0.12 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 179.266 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -126.17 136.1 52.45 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.941 0.4 . . . . 0.0 111.126 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 92.8 t80 -60.05 131.34 50.54 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.997 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -115.59 114.17 42.46 Favored Pre-proline 0 C--N 1.329 -0.303 0 CA-C-N 115.755 -0.657 . . . . 0.0 109.884 179.088 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -72.26 -30.76 12.6 Favored 'Trans proline' 0 C--N 1.315 -1.189 0 C-N-CA 121.217 1.278 . . . . 0.0 111.452 -179.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.13 -45.22 97.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.326 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.361 178.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.425 HD12 HG21 ' A' ' 17' ' ' THR . 82.4 mt -85.36 -22.08 28.6 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.442 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.64 -0.5 89.55 Favored Glycine 0 CA--C 1.53 0.999 0 CA-C-N 116.131 -0.486 . . . . 0.0 112.16 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -141.05 176.56 4.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 C-N-CA 120.784 -0.366 . . . . 0.0 110.734 179.703 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 93.0 m -88.05 139.89 30.05 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.02 0.438 . . . . 0.0 111.149 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.425 HG21 HD12 ' A' ' 13' ' ' LEU . 80.5 p -129.15 156.7 43.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.962 179.605 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt -67.76 148.43 11.95 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.246 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.51 ' O ' HD22 ' A' ' 20' ' ' LEU . 76.6 p -128.82 153.69 47.17 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.312 179.738 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.51 HD22 ' O ' ' A' ' 19' ' ' THR . 0.4 OUTLIER -134.66 -23.07 1.63 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.455 179.944 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.474 ' O ' ' CB ' ' A' ' 22' ' ' ARG . 66.0 m -127.14 149.26 50.04 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.524 -179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . 0.474 ' CB ' ' O ' ' A' ' 21' ' ' SER . 5.3 tpp85 . . . . . 0 C--O 1.221 -0.428 0 CA-C-O 117.916 -1.04 . . . . 0.0 110.501 -179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 71.1 tp60 . . . . . 0 C--O 1.232 0.169 0 CA-C-O 120.642 0.258 . . . . 0.0 110.461 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.2 t90 -107.99 129.53 55.11 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.711 -179.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 73.5 m -114.96 149.41 37.38 Favored 'General case' 0 C--N 1.332 -0.172 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.327 179.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.699 ' NE2' ' H ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -72.26 162.69 72.44 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.76 179.407 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -64.96 138.98 59.62 Favored 'Trans proline' 0 C--N 1.302 -1.906 0 C-N-CA 121.734 1.623 . . . . 0.0 110.767 179.43 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.34 -6.9 83.04 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 -178.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 26.2 m-85 -112.73 144.24 42.59 Favored 'General case' 0 C--N 1.331 -0.207 0 N-CA-C 110.181 -0.303 . . . . 0.0 110.181 179.699 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.92 133.76 55.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.35 179.92 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.0 t80 -63.82 130.67 45.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.938 -179.839 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.04 112.09 50.23 Favored Pre-proline 0 CA--C 1.532 0.273 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.449 179.306 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -74.05 -32.19 7.2 Favored 'Trans proline' 0 C--N 1.317 -1.1 0 C-N-CA 121.397 1.398 . . . . 0.0 111.367 -179.786 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.8 -44.89 96.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.547 179.296 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.539 HD12 HG21 ' A' ' 17' ' ' THR . 76.8 mt -83.38 -22.51 32.74 Favored 'General case' 0 CA--C 1.53 0.186 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.197 -179.657 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.18 2.3 90.47 Favored Glycine 0 CA--C 1.53 0.975 0 CA-C-N 116.151 -0.477 . . . . 0.0 112.617 179.003 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.2 179.72 3.16 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.217 0 CA-C-N 117.308 0.554 . . . . 0.0 111.073 179.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 59.7 m -88.33 137.13 32.6 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.161 -0.472 . . . . 0.0 109.813 179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.539 HG21 HD12 ' A' ' 13' ' ' LEU . 82.6 p -128.18 156.75 42.42 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-O 121.038 0.447 . . . . 0.0 110.826 -179.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.468 HG12 ' H ' ' A' ' 20' ' ' LEU . 11.0 tt -80.46 142.47 13.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.241 0 CA-C-N 115.859 -0.609 . . . . 0.0 110.553 -179.109 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 77.1 p -106.3 8.47 31.84 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.232 0.539 . . . . 0.0 110.966 -179.647 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.468 ' H ' HG12 ' A' ' 18' ' ' ILE . 61.4 tp -107.32 123.33 48.18 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-N 115.166 -0.925 . . . . 0.0 110.457 -179.705 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.3 t -149.98 143.9 25.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.421 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 66.1 ttp85 . . . . . 0 C--O 1.22 -0.48 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.569 179.923 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 7.5 tp-100 . . . . . 0 C--O 1.23 0.068 0 CA-C-O 120.925 0.393 . . . . 0.0 110.441 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.8 t90 -66.54 133.22 49.91 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.709 179.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 71.2 m -118.9 150.51 39.76 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.47 179.8 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.682 ' NE2' ' H ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -73.49 162.03 76.21 Favored Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.718 179.243 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -66.04 138.29 51.72 Favored 'Trans proline' 0 C--N 1.304 -1.812 0 C-N-CA 121.772 1.648 . . . . 0.0 110.77 179.401 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.54 -7.35 82.09 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 -179.02 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 21.3 m-85 -112.04 142.68 44.17 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 179.565 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.41 133.94 54.22 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.558 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.52 130.79 45.82 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.913 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -114.14 112.99 46.62 Favored Pre-proline 0 CA--C 1.533 0.289 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.272 179.099 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -73.78 -32.79 7.05 Favored 'Trans proline' 0 C--N 1.315 -1.215 0 C-N-CA 121.301 1.334 . . . . 0.0 111.454 -179.847 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 63.6 t -64.27 -45.66 95.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.497 179.361 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.446 HD12 HG21 ' A' ' 17' ' ' THR . 84.1 mt -81.38 -24.66 36.86 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.395 -179.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 85.01 1.53 88.72 Favored Glycine 0 CA--C 1.532 1.151 0 CA-C-N 116.189 -0.46 . . . . 0.0 112.595 179.139 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.446 HD13 ' H ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -139.1 179.31 3.13 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-N 117.47 0.635 . . . . 0.0 111.043 179.614 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 37.4 m -88.97 135.58 33.47 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 109.878 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.446 HG21 HD12 ' A' ' 13' ' ' LEU . 82.7 p -127.65 154.59 45.09 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-O 121.005 0.431 . . . . 0.0 110.805 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.3 tt -72.03 153.97 7.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.459 -179.35 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 72.3 p -132.2 148.69 52.47 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 109.777 -0.453 . . . . 0.0 109.777 179.772 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 85.0 mt -140.45 145.99 37.67 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.611 -179.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 98.9 p -64.03 -23.47 67.35 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.658 179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 78.2 ttt-85 . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 117.968 -1.015 . . . . 0.0 110.58 -179.948 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 25.5 pt20 . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.859 0.361 . . . . 0.0 110.496 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.7 t90 -65.71 134.14 52.56 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.906 -179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.1 m -115.93 149.61 38.46 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.252 179.687 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.675 ' NE2' ' H ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -75.64 162.31 72.82 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-N 115.935 -0.575 . . . . 0.0 109.975 179.504 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_endo -65.68 139.54 58.4 Favored 'Trans proline' 0 C--N 1.303 -1.848 0 C-N-CA 121.77 1.647 . . . . 0.0 110.779 179.213 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.3 -7.55 81.78 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.154 -1.179 . . . . 0.0 110.154 -178.807 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 26.1 m-85 -112.37 143.93 42.66 Favored 'General case' 0 N--CA 1.462 0.157 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.2 134.22 54.68 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.551 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 86.9 t80 -63.4 130.97 46.7 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.891 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -114.56 112.07 46.01 Favored Pre-proline 0 CA--C 1.534 0.344 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.337 179.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -73.88 -32.32 7.36 Favored 'Trans proline' 0 C--N 1.316 -1.134 0 C-N-CA 121.338 1.359 . . . . 0.0 111.413 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.5 t -64.71 -45.07 96.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.246 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.684 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.59 HD12 HG21 ' A' ' 17' ' ' THR . 76.8 mt -83.06 -22.65 33.44 Favored 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.117 -179.573 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.25 2.66 90.37 Favored Glycine 0 CA--C 1.53 0.974 0 CA-C-N 116.168 -0.469 . . . . 0.0 112.51 179.013 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.401 ' C ' HD13 ' A' ' 15' ' ' ILE . 0.0 OUTLIER -138.68 179.54 3.12 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 117.209 0.505 . . . . 0.0 111.07 179.979 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 38.3 m -88.78 134.94 33.77 Favored 'General case' 0 C--N 1.329 -0.306 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.59 HG21 HD12 ' A' ' 13' ' ' LEU . 80.2 p -126.55 154.46 43.83 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 121.012 0.434 . . . . 0.0 110.73 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.2 tt -72.03 155.52 7.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.363 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.791 -179.158 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 76.1 p -129.19 157.81 40.78 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.162 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 1.4 pp -130.11 -16.87 3.54 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.695 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 40.6 t -63.12 139.36 58.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.515 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 66.9 ttp85 . . . . . 0 C--O 1.22 -0.472 0 CA-C-O 117.973 -1.013 . . . . 0.0 110.496 -179.97 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 4.9 pp0? . . . . . 0 C--O 1.231 0.081 0 CA-C-O 120.759 0.314 . . . . 0.0 110.591 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 89.6 t90 -138.29 131.62 30.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.869 -179.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.0 m -120.5 149.64 42.1 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 121.102 0.477 . . . . 0.0 110.544 179.335 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.441 ' NE2' ' CZ ' ' A' ' 7' ' ' TYR . 4.2 pt20 -69.14 158.74 85.75 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.124 179.679 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -55.46 137.69 78.29 Favored 'Trans proline' 0 N--CA 1.499 1.801 0 C-N-CA 121.533 1.488 . . . . 0.0 112.028 179.513 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 87.13 2.36 83.55 Favored Glycine 0 CA--C 1.53 1.018 0 N-CA-C 111.783 -0.527 . . . . 0.0 111.783 179.39 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . 0.441 ' CZ ' ' NE2' ' A' ' 4' ' ' GLN . 38.6 m-85 -120.29 143.61 48.25 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.743 0.306 . . . . 0.0 110.559 179.603 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -111.42 130.1 55.81 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.922 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 93.3 t80 -63.87 130.96 46.25 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.865 -179.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.3 m120 -112.24 112.99 51.83 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.108 179.214 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -73.35 -31.81 8.79 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.266 1.31 . . . . 0.0 111.487 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.3 t -64.59 -45.89 94.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.363 179.13 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.0 mt -82.25 -27.14 32.63 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.365 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.67 3.69 90.4 Favored Glycine 0 CA--C 1.528 0.881 0 N-CA-C 111.415 -0.674 . . . . 0.0 111.415 179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.601 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.4 pp -133.46 173.03 15.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-O 120.878 0.37 . . . . 0.0 110.923 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 69.0 m -88.33 136.38 33.01 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.065 -179.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.2 p -126.39 151.26 47.89 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-O 120.958 0.408 . . . . 0.0 110.628 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.3 tt -72.88 152.29 7.71 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.563 -179.078 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 59.4 p -131.93 149.3 52.48 Favored 'General case' 0 N--CA 1.454 -0.255 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 179.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.8 mt -140.04 146.87 39.55 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.575 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 98.7 p -63.42 -23.09 67.25 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.506 179.879 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 60.2 ttp180 . . . . . 0 C--O 1.22 -0.475 0 CA-C-O 117.935 -1.031 . . . . 0.0 110.455 179.992 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.889 0.376 . . . . 0.0 110.609 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.8 t90 -66.45 132.03 47.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.738 -179.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.9 m -118.54 150.24 39.97 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.429 179.639 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.695 ' NE2' ' H ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -72.55 162.39 74.34 Favored Pre-proline 0 C--N 1.325 -0.464 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.729 179.276 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -65.12 138.94 58.68 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 C-N-CA 121.663 1.576 . . . . 0.0 110.831 179.241 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.1 -6.61 83.46 Favored Glycine 0 CA--C 1.529 0.93 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 -178.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.7 m-85 -113.28 143.6 44.14 Favored 'General case' 0 C--N 1.331 -0.208 0 N-CA-C 110.246 -0.279 . . . . 0.0 110.246 179.664 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.25 133.89 54.86 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.423 179.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 89.2 t80 -63.48 131.03 46.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.045 -179.807 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -113.98 112.12 47.59 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.404 179.288 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -73.99 -32.13 7.36 Favored 'Trans proline' 0 C--N 1.316 -1.147 0 C-N-CA 121.349 1.366 . . . . 0.0 111.458 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.5 t -64.68 -45.13 96.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.573 179.215 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.556 HD12 HG21 ' A' ' 17' ' ' THR . 77.7 mt -82.63 -22.77 34.6 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.254 -179.726 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.35 2.37 90.28 Favored Glycine 0 CA--C 1.529 0.955 0 CA-C-N 116.086 -0.506 . . . . 0.0 112.574 179.195 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.98 179.43 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.172 0 CA-C-N 117.209 0.504 . . . . 0.0 111.027 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.4 m -88.81 136.3 33.07 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.028 -0.533 . . . . 0.0 109.774 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.556 HG21 HD12 ' A' ' 13' ' ' LEU . 81.9 p -127.66 156.22 42.68 Favored 'General case' 0 N--CA 1.462 0.138 0 CA-C-O 120.98 0.419 . . . . 0.0 110.816 -179.783 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.463 HG12 ' H ' ' A' ' 20' ' ' LEU . 10.8 tt -78.95 142.86 13.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.495 -179.258 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 75.4 p -105.2 7.88 33.8 Favored 'General case' 0 CA--C 1.519 -0.219 0 CA-C-O 121.285 0.564 . . . . 0.0 111.004 -179.679 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.463 ' H ' HG12 ' A' ' 18' ' ' ILE . 61.3 tp -108.43 123.02 48.21 Favored 'General case' 0 C--N 1.315 -0.916 0 CA-C-N 115.186 -0.916 . . . . 0.0 110.3 -179.824 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 69.0 m -68.79 147.66 51.45 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.66 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 39.7 ttm105 . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 117.993 -1.003 . . . . 0.0 110.556 179.827 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 5.5 tm0? . . . . . 0 C--O 1.23 0.078 0 CA-C-O 120.784 0.326 . . . . 0.0 110.382 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.0 t90 -139.77 131.4 27.24 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.774 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 73.0 m -119.18 148.73 42.77 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.367 179.515 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.64 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -69.89 159.25 84.85 Favored Pre-proline 0 C--N 1.327 -0.401 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.613 179.072 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.1 Cg_endo -63.18 139.58 73.14 Favored 'Trans proline' 0 C--N 1.302 -1.892 0 C-N-CA 121.631 1.554 . . . . 0.0 111.035 179.642 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 90.3 -6.46 82.44 Favored Glycine 0 CA--C 1.529 0.911 0 N-CA-C 110.411 -1.075 . . . . 0.0 110.411 -178.885 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 29.9 m-85 -114.79 144.35 43.64 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-O 120.666 0.269 . . . . 0.0 110.406 179.754 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.59 133.3 54.7 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.243 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.5 t80 -63.28 131.16 47.44 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.857 -179.813 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.89 112.22 47.79 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.504 179.345 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -74.38 -31.74 7.05 Favored 'Trans proline' 0 C--N 1.317 -1.112 0 C-N-CA 121.374 1.383 . . . . 0.0 111.271 -179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.1 t -64.67 -44.94 96.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.47 179.198 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.532 HD12 HG21 ' A' ' 17' ' ' THR . 76.9 mt -83.8 -22.51 31.78 Favored 'General case' 0 CA--C 1.529 0.154 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.262 -179.572 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.44 2.14 90.19 Favored Glycine 0 CA--C 1.531 1.042 0 CA-C-N 116.199 -0.455 . . . . 0.0 112.573 179.125 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.4 HD13 ' C ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -138.07 -179.11 2.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-N 117.214 0.507 . . . . 0.0 111.018 179.937 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 57.7 m -90.8 134.96 34.04 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.177 -0.465 . . . . 0.0 109.84 179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.532 HG21 HD12 ' A' ' 13' ' ' LEU . 78.5 p -127.1 153.28 46.2 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-O 120.95 0.405 . . . . 0.0 110.877 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.3 tt -72.22 154.22 7.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.652 -179.16 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 60.0 p -128.73 157.35 41.64 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.242 -179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 59.9 tp -135.73 -89.24 0.32 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.365 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 97.5 p -64.6 -23.73 67.36 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.412 -0.358 . . . . 0.0 110.593 179.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 40.2 ptt180 . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.657 -179.925 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 64.1 tt0 . . . . . 0 C--O 1.232 0.17 0 CA-C-O 120.794 0.331 . . . . 0.0 110.566 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 92.2 t90 -67.25 132.26 47.39 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.769 -179.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 71.4 m -118.01 149.88 40.21 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.203 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.693 ' NE2' ' H ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -72.73 161.98 76.54 Favored Pre-proline 0 C--N 1.325 -0.493 0 CA-C-N 116.067 -0.515 . . . . 0.0 109.75 179.431 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_endo -65.8 138.48 53.51 Favored 'Trans proline' 0 C--N 1.302 -1.901 0 C-N-CA 121.699 1.6 . . . . 0.0 110.846 179.399 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.5 -7.15 82.52 Favored Glycine 0 CA--C 1.527 0.798 0 N-CA-C 110.167 -1.173 . . . . 0.0 110.167 -178.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 21.9 m-85 -112.12 143.05 43.8 Favored 'General case' 0 C--N 1.332 -0.162 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.63 133.86 54.45 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.629 -179.848 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 84.3 t80 -63.2 130.48 44.75 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.808 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.18 112.22 49.77 Favored Pre-proline 0 CA--C 1.533 0.296 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.347 179.203 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -73.84 -32.11 7.63 Favored 'Trans proline' 0 C--N 1.316 -1.16 0 C-N-CA 121.282 1.322 . . . . 0.0 111.369 -179.91 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 63.7 t -64.4 -45.07 96.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.505 179.136 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.492 HD12 HG21 ' A' ' 17' ' ' THR . 78.4 mt -83.6 -23.53 31.86 Favored 'General case' 0 CA--C 1.529 0.161 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.294 -179.561 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.09 1.63 89.59 Favored Glycine 0 CA--C 1.53 0.995 0 CA-C-N 116.35 -0.386 . . . . 0.0 112.569 178.992 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.407 HD13 ' H ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -138.15 177.41 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 117.347 0.574 . . . . 0.0 110.975 179.727 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 39.3 m -87.76 135.27 33.45 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 -179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.492 HG21 HD12 ' A' ' 13' ' ' LEU . 81.5 p -127.51 154.47 45.1 Favored 'General case' 0 N--CA 1.462 0.146 0 CA-C-O 120.926 0.393 . . . . 0.0 110.853 -179.823 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.6 tt -72.02 153.25 7.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.457 -179.397 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 68.2 p -131.55 148.65 52.64 Favored 'General case' 0 N--CA 1.453 -0.297 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.803 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 87.0 mt -141.18 145.46 35.7 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.619 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 83.7 p -71.21 160.82 32.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.449 179.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 83.7 mtt85 . . . . . 0 C--O 1.219 -0.506 0 CA-C-O 117.979 -1.01 . . . . 0.0 110.608 179.901 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 . . . . . 0 C--O 1.231 0.114 0 CA-C-O 121.07 0.462 . . . . 0.0 110.349 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.0 t90 -69.96 132.6 46.2 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.936 -179.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 77.9 m -116.02 138.05 51.57 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.24 179.698 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.656 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 3.9 pm0 -72.61 158.78 86.8 Favored Pre-proline 0 CA--C 1.535 0.391 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.772 179.833 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 61.2 Cg_exo -54.32 140.01 73.11 Favored 'Trans proline' 0 N--CA 1.497 1.727 0 C-N-CA 121.23 1.287 . . . . 0.0 111.568 179.194 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 90.81 -8.63 79.52 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.737 -0.945 . . . . 0.0 110.737 -179.71 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 33.1 m-85 -117.16 140.35 49.63 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 110.273 -0.269 . . . . 0.0 110.273 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -112.99 133.76 54.8 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.349 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 88.2 t80 -62.44 131.47 49.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.921 -179.768 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -114.07 112.26 47.26 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.393 179.028 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -73.61 -31.79 8.36 Favored 'Trans proline' 0 N--CA 1.487 1.103 0 C-N-CA 121.373 1.382 . . . . 0.0 111.404 -179.682 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.0 t -64.93 -44.85 96.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.412 179.333 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.511 HD12 HG21 ' A' ' 17' ' ' THR . 77.0 mt -83.85 -23.64 31.25 Favored 'General case' 0 CA--C 1.53 0.189 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.27 -179.602 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.84 1.62 89.84 Favored Glycine 0 CA--C 1.531 1.077 0 CA-C-N 116.073 -0.512 . . . . 0.0 112.53 179.027 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.16 177.85 4.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 117.349 0.575 . . . . 0.0 111.056 179.807 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 63.1 m -86.29 137.26 32.74 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.13 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.511 HG21 HD12 ' A' ' 13' ' ' LEU . 76.6 p -128.15 154.37 45.85 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-O 120.797 0.332 . . . . 0.0 110.746 179.863 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.5 tt -74.66 151.57 6.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.585 -179.202 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 68.2 p -129.8 155.42 46.0 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.1 179.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . . . . . . . . . 60.0 tp -119.45 -38.12 3.06 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.949 -0.568 . . . . 0.0 110.202 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 93.8 p -153.05 161.83 42.04 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.489 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 78.1 ttt-85 . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.993 -1.004 . . . . 0.0 110.531 -179.945 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 22.0 mp0 . . . . . 0 C--O 1.232 0.162 0 CA-C-O 120.824 0.345 . . . . 0.0 110.628 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 90.7 t90 -67.69 128.95 38.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.716 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 79.8 m -120.73 128.06 52.58 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.393 179.781 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.687 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 1.0 OUTLIER -53.12 154.37 5.53 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.536 -179.46 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 29.9 Cg_endo -64.39 146.97 90.63 Favored 'Trans proline' 0 C--N 1.31 -1.481 0 C-N-CA 121.574 1.516 . . . . 0.0 111.024 179.597 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 92.06 -7.9 78.3 Favored Glycine 0 CA--C 1.527 0.788 0 N-CA-C 110.016 -1.234 . . . . 0.0 110.016 -178.519 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 28.6 m-85 -109.89 146.58 34.9 Favored 'General case' 0 C--O 1.233 0.189 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 179.181 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -124.92 135.39 52.8 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.936 0.398 . . . . 0.0 111.151 -179.469 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -60.29 131.19 50.02 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.782 -0.645 . . . . 0.0 111.113 179.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.4 114.17 48.02 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-N 115.735 -0.666 . . . . 0.0 109.696 178.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -71.82 -30.34 14.36 Favored 'Trans proline' 0 C--N 1.316 -1.164 0 C-N-CA 121.304 1.336 . . . . 0.0 111.525 -179.539 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.3 t -64.2 -45.42 96.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.141 178.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . . . . . . . . . 84.0 mt -85.43 -24.43 27.47 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.436 -179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.21 0.89 90.16 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 111.083 -0.807 . . . . 0.0 111.083 -179.822 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.629 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.5 pp -135.66 171.16 17.75 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 120.661 0.267 . . . . 0.0 110.557 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 96.7 m -88.06 141.23 28.73 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.975 0.417 . . . . 0.0 111.015 -179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 80.8 p -128.99 157.05 42.77 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.116 179.465 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 13.0 tt -69.62 147.24 11.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.446 -179.545 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.515 ' C ' HD13 ' A' ' 20' ' ' LEU . 75.4 p -127.38 153.19 46.53 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.306 179.634 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.851 ' N ' HD13 ' A' ' 20' ' ' LEU . 0.0 OUTLIER -141.65 170.72 15.18 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.141 0.496 . . . . 0.0 111.027 179.983 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 68.2 m -71.9 148.39 46.13 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.581 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 84.4 mtp180 . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.65 179.903 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 7.3 tp-100 . . . . . 0 C--O 1.23 0.075 0 CA-C-O 120.922 0.392 . . . . 0.0 110.4 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 92.0 t90 -67.66 132.58 47.76 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.79 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.8 m -117.57 150.67 38.6 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.216 179.608 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.687 ' NE2' ' H ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -73.89 162.02 75.96 Favored Pre-proline 0 C--N 1.325 -0.473 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.908 179.446 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -65.7 138.68 54.77 Favored 'Trans proline' 0 C--N 1.302 -1.887 0 C-N-CA 121.799 1.666 . . . . 0.0 110.757 179.398 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.62 -7.2 82.35 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.18 -1.168 . . . . 0.0 110.18 -178.836 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 23.0 m-85 -112.57 143.35 43.89 Favored 'General case' 0 C--N 1.332 -0.173 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 179.506 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -114.12 133.9 55.25 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.598 -179.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 85.6 t80 -62.94 131.02 47.3 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.917 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.6 m120 -113.96 112.77 47.26 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.262 179.222 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -73.39 -32.52 7.98 Favored 'Trans proline' 0 C--N 1.316 -1.182 0 C-N-CA 121.34 1.36 . . . . 0.0 111.436 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 64.7 t -64.86 -45.29 95.36 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.653 179.274 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.529 HD12 HG21 ' A' ' 17' ' ' THR . 81.5 mt -81.91 -24.34 35.7 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.363 -179.67 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.21 1.51 89.51 Favored Glycine 0 CA--C 1.531 1.051 0 CA-C-N 116.214 -0.448 . . . . 0.0 112.639 179.122 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.42 HD13 ' H ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -139.06 176.9 5.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 117.366 0.583 . . . . 0.0 111.032 179.67 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 38.8 m -85.78 135.25 33.81 Favored 'General case' 0 C--N 1.331 -0.229 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.529 HG21 HD12 ' A' ' 13' ' ' LEU . 82.6 p -127.95 155.26 44.52 Favored 'General case' 0 N--CA 1.462 0.139 0 CA-C-O 120.978 0.418 . . . . 0.0 110.845 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 11.3 tt -74.0 154.45 6.81 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.582 -179.348 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 58.7 p -128.89 156.56 43.49 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.293 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.765 ' N ' HD23 ' A' ' 20' ' ' LEU . 1.4 pt? -155.78 159.17 39.22 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.7 -179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 83.2 p -70.97 160.33 33.09 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.497 179.915 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 82.4 mtp180 . . . . . 0 C--O 1.219 -0.511 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.529 179.975 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 96.8 mt-30 . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.722 0.296 . . . . 0.0 110.651 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.8 t90 -140.73 134.37 30.2 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.631 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 77.2 m -118.69 149.98 40.52 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.662 179.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.687 ' NE2' ' H ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -73.92 162.5 73.76 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 115.815 -0.629 . . . . 0.0 109.853 179.263 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 29.3 Cg_endo -65.1 138.73 57.85 Favored 'Trans proline' 0 C--N 1.302 -1.911 0 C-N-CA 121.637 1.558 . . . . 0.0 110.703 179.343 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 89.56 -7.35 82.08 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 110.158 -1.177 . . . . 0.0 110.158 -178.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 25.9 m-85 -112.97 144.72 42.06 Favored 'General case' 0 N--CA 1.462 0.138 0 N-CA-C 110.128 -0.323 . . . . 0.0 110.128 179.678 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -113.93 133.89 55.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.548 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 90.3 t80 -63.66 130.92 46.27 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.82 179.988 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.7 m120 -113.28 112.27 49.46 Favored Pre-proline 0 CA--C 1.533 0.301 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.403 179.349 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -74.21 -31.99 7.12 Favored 'Trans proline' 0 C--N 1.317 -1.108 0 C-N-CA 121.399 1.399 . . . . 0.0 111.337 -179.802 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 60.9 t -64.5 -45.01 96.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.513 179.216 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.491 HD12 HG21 ' A' ' 17' ' ' THR . 74.9 mt -83.66 -22.75 32.05 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.325 -179.351 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 83.39 2.47 90.22 Favored Glycine 0 CA--C 1.53 1.003 0 CA-C-N 116.245 -0.434 . . . . 0.0 112.456 179.115 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.412 HD13 ' C ' ' A' ' 15' ' ' ILE . 0.0 OUTLIER -138.23 -179.87 2.86 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 CA-C-N 117.23 0.515 . . . . 0.0 111.07 179.962 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 59.1 m -90.3 135.56 33.6 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.095 -0.502 . . . . 0.0 109.953 179.836 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.491 HG21 HD12 ' A' ' 13' ' ' LEU . 82.5 p -127.89 154.46 45.48 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 120.98 0.419 . . . . 0.0 110.792 179.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 10.7 tt -72.88 154.61 7.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.568 -179.342 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 70.6 p -128.48 157.53 40.87 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.364 179.862 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.791 ' N ' HD23 ' A' ' 20' ' ' LEU . 1.5 pt? -152.01 162.36 41.21 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.694 -179.896 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.0 t -60.92 -44.6 96.98 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.459 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 . . . . . 0 C--O 1.219 -0.515 0 CA-C-O 117.876 -1.059 . . . . 0.0 110.484 179.917 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 4.9 mm100 . . . . . 0 C--O 1.232 0.173 0 CA-C-O 120.724 0.297 . . . . 0.0 110.543 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.1 t90 -67.75 128.98 38.48 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.765 -179.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 82.0 m -121.38 128.4 52.18 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.405 179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.656 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 1.3 pm0 -53.79 154.19 7.38 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.499 -179.504 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -64.5 147.26 90.37 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 121.548 1.499 . . . . 0.0 110.853 179.68 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 92.39 -7.4 77.96 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -178.383 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 32.6 m-85 -112.04 145.98 38.72 Favored 'General case' 0 C--N 1.333 -0.116 0 N-CA-C 109.662 -0.496 . . . . 0.0 109.662 179.265 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -124.13 135.86 53.81 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.083 0.468 . . . . 0.0 111.137 -179.257 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 89.8 t80 -60.34 131.51 51.0 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.631 -0.713 . . . . 0.0 111.196 179.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -113.99 114.43 46.34 Favored Pre-proline 0 CA--C 1.533 0.318 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.61 178.829 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -71.93 -30.76 13.49 Favored 'Trans proline' 0 C--N 1.315 -1.188 0 C-N-CA 121.255 1.303 . . . . 0.0 111.708 -179.396 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.2 t -64.26 -45.45 96.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.264 178.977 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.414 HD12 HG21 ' A' ' 17' ' ' THR . 84.7 mt -84.54 -24.76 29.16 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.409 -179.818 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.34 0.74 90.09 Favored Glycine 0 CA--C 1.527 0.831 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 -179.738 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.638 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.5 pp -135.26 171.68 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-O 120.597 0.237 . . . . 0.0 110.463 179.806 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 92.4 m -88.79 140.94 28.93 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.073 0.464 . . . . 0.0 110.976 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.414 HG21 HD12 ' A' ' 13' ' ' LEU . 80.8 p -128.41 155.92 43.98 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.838 179.506 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 12.4 tt -67.43 143.3 15.57 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.139 -179.421 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . . . . . . . . . 9.7 t -144.86 146.66 32.16 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.606 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.837 ' N ' HD23 ' A' ' 20' ' ' LEU . 0.3 OUTLIER -132.22 36.2 3.64 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.438 -179.702 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 40.8 t -63.49 139.7 58.8 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.432 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 43.5 ttm180 . . . . . 0 C--O 1.22 -0.481 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.534 -179.977 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 79.1 mt-30 . . . . . 0 C--O 1.232 0.154 0 CA-C-O 120.941 0.4 . . . . 0.0 110.391 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' TRP . . . . . . . . . . . . . 91.1 t90 -70.54 133.89 47.19 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.938 -179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 70.8 m -118.17 148.35 42.45 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.389 179.672 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLN . . . . . 0.662 ' H ' ' CD ' ' A' ' 4' ' ' GLN . 0.0 OUTLIER -73.56 158.49 86.32 Favored Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.638 179.032 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_endo -61.58 140.32 86.27 Favored 'Trans proline' 0 C--N 1.304 -1.783 0 C-N-CA 121.629 1.553 . . . . 0.0 111.056 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 91.25 -8.39 79.4 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.353 -1.099 . . . . 0.0 110.353 -178.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 46.9 m-85 -113.94 142.07 46.6 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 120.648 0.261 . . . . 0.0 110.426 179.576 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -110.24 132.49 54.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.082 179.474 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 92.4 t80 -64.03 131.64 48.19 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.012 -179.637 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -112.73 113.63 50.09 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.122 178.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -73.3 -32.71 7.93 Favored 'Trans proline' 0 C--N 1.316 -1.144 0 C-N-CA 121.257 1.305 . . . . 0.0 111.598 -179.646 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 62.3 t -64.38 -46.03 94.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.529 179.262 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LEU . . . . . 0.429 HD12 HG21 ' A' ' 17' ' ' THR . 84.6 mt -81.54 -27.07 34.55 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.303 -179.942 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 82.73 2.99 90.69 Favored Glycine 0 CA--C 1.528 0.845 0 N-CA-C 111.342 -0.703 . . . . 0.0 111.342 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ILE . . . . . 0.619 ' C ' HD12 ' A' ' 15' ' ' ILE . 2.4 pp -133.03 173.44 14.83 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.173 0 CA-C-O 120.865 0.364 . . . . 0.0 110.689 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' CYS . . . . . . . . . . . . . 48.3 m -87.8 136.89 32.76 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.039 -179.578 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.429 HG21 HD12 ' A' ' 13' ' ' LEU . 82.3 p -128.55 154.23 46.38 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 121.372 0.606 . . . . 0.0 111.287 -179.881 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.74 HD13 ' H ' ' A' ' 19' ' ' THR . 0.4 OUTLIER -72.86 141.79 15.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 115.223 -0.898 . . . . 0.0 110.462 -179.877 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' THR . . . . . 0.74 ' H ' HD13 ' A' ' 18' ' ' ILE . 11.2 t -144.76 149.46 35.56 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.248 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' LEU . . . . . 0.805 ' N ' HD23 ' A' ' 20' ' ' LEU . 1.5 pt? -151.95 165.12 35.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.941 -179.826 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 48.1 t -61.09 -43.53 98.74 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.923 -179.776 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ARG . . . . . . . . . . . . . 60.1 ttt85 . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.995 -1.002 . . . . 0.0 110.394 -179.627 . . . . . . . . 0 0 . 1 stop_ save_